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Summary 
Oncogenic activation of MYC drives cell proliferation in Burkitt lymphoma (BL), but also evokes 
stress signals that have to be counterbalanced to escape apoptosis. Pro-survival signals from 
tonic B cell receptor and PI3K signaling are essential, but additional mutations are required for 
malignant transformation.  
TP53 mutations were identified in 43% of BL patients. Mutations in the conserved MYC box I 
that abrogate activation of pro-apoptotic Bcl2-family member Bim were present in 17% of BL 
patients. Notably, MYC box I and TP53 mutations occurred independently and accounted for 
54% of cases, suggesting that alternative failsafe mechanisms may be inactivated in BL. To 
study alternative mechanisms of transformation in the absence of TP53 mutations, we 
analyzed the pattern of recurrent genetic aberrations in BL for associations with TP53 status. 
We observed an overrepresentation of chromosome 1q gains in TP53 wild-type BL patients, 
which was not observed in diffuse large B cell lymphoma (DLBCL) patients. Minimally gained 
regions comprised 1q21-q23 and 1q32 and amplified regions displayed a gene dosage effect as 
shown by gene expression analysis. 
To identify genes essential for p53 wild-type BL cells we performed a RNAi loss-of-function 
screen in a panel of genetically defined cell lines. We used a pooled shRNA library targeting 
5,000 genes in key signaling pathways across the genome. Our data was probed against 
published RNAi screens across cancer entities and showed a high overlap of common essential 
and non-essential genes. p53 wild-type BL cell lines showed a strong and specific dependence 
on the p53 inhibitor MDM4. Depletion of MDM4 resulted in an upregulation of p53 target 
genes and induced cell cycle arrest. In a mouse xenograft model, MDM4 knock-down 
significantly reduced tumor growth. These effects were p53 dependent as confirmed in an 
isogenic p53 knock-out cell line. MDM4 is located within the minimally gained region 1q32 
associated with p53 wild-type BL patients and might therefore contribute to BL pathogenesis 
by inactivation of the p53 pathway. Our data suggest that reactivation of p53 in patients 
lacking TP53 mutation, e.g. by specific MDM4 inhibition, is a promising therapeutic approach. 
Re-analysis of published RNAi screening data revealed p53-specific sensitivity of MDM4 knock-
down across cancer cell lines, suggesting a broader application for MDM4 inhibitors. 
Our data set on essential genes in Burkitt lymphoma proved to be a valuable resource for 
identification of genotype-specific vulnerabilities. This analysis could be extended by 
integration of published RNAi screening data in non-lymphoid cell lines to identify interesting 
potential entity-specific vulnerabilities. 
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Zusammenfassung 
Das Onkogen MYC ist überexprimiert im Burkitt Lymphom (BL) und fördert das Zellwachstum. 
Gleichzeitig löst MYC Stresssignale aus, die durch überlebensfördernde Signale kompensiert 
werden, um Apoptose vorzubeugen. Neben tonischer B-Zell-Rezeptor Aktivität und 
konstitutivem PI3K-Signalweg tragen genetische Mutationen zur malignen Transformation bei. 
43% aller Patienten weisen Mutation im Tumorsuppressorgen TP53 auf und 17% in der 
konservierten MYC Box I-Region. Beide Mutationen können die Aktivierung apoptotischer 
Programme verhindern. Nach unseren Beobachtungen treten diese Mutationen unabhängig 
voneinander auf und betreffen 54% aller Patienten. Dies lässt vermuten, dass es weitere 
Sicherheitsmechanismen gibt, die im BL deaktiviert sind.  
Um Alternativen zu TP53 Mutationen zu identifizieren, haben wir genetische Informationen 
aus Primärmaterial mit Daten aus einem funktionellen Screen in Zelllinienmodellen integriert. 
Ein Zugewinn auf dem q-Arm von Chromosom 1 war überrepräsentiert in BL Patienten mit 
TP53 Wildtyp-Gen, aber unabhängig von p53 in Patienten mit diffus großzelligem B-Zell-
Lymphom. Die Regionen minimalen Zugewinns umfassten 1q21-23 und 1q32 und korrelierten 
mit der Genexpression. 
Um Gene zu identifizieren, die in Anwesenheit von Wildtyp p53 essentiell sind, wurde ein RNA-
Interferenz (RNAi) Screen mit einem Pool aus short-hairpin RNAs (shRNAs), gerichtet gegen 
5000 Gene in zentralen Signalwegen, in genetisch definierten Zelllinien durchgeführt. Gene, 
die basierend auf früheren RNAi Screens in verscheidenen Krebsentitäten als essentiell oder 
nicht-essentiell klassifiziert wurden, wiesen eine hohe Übereinstimmung mit unseren Daten 
auf. p53 Wildtyp Zelllinien zeigten zudem eine starke und spezifische Abhängigkeit vom p53 
Inhibitor MDM4. Herunterregulation von MDM4 führte zur Aktivierung des p53 Signalweges 
und löste Zellzyklusarrest aus. Reduzierte MDM4 Expression unterdrückte darüber hinaus das 
Wachstum eines Heterotransplants in immunsuppremierten Mäusen. Wie an einem 
Zelllinienmodel mit genetisch inaktiviertem p53 gezeigt werden konnte, waren alle Effekte 
p53-abhängig.  
MDM4 liegt auf 1q32. Chromosomaler Zugewinn dieser Region könnte zur Inaktivierung von 
p53 und somit zur Pathogenese von p53 Wildtyp BL Patienten beitragen. Unsere Daten lassen 
vermuten, dass Reaktivierung von p53, z.B. durch MDM4 Inhbitoren, in Patienten ohne TP53 
Mutation ein vielversprechender therapeutischer Ansatz ist. Durch Metaanalyse eines 
öffentlichen RNAi Screens wurde eine p53-spezifische Abhängigkeit von MDM4 in Zelllinien 
unterschiedlicher Entitäten beobachtet. Dies lässt vermuten, dass MDM4 Inhibitoren für eine 
breite Anwendung verwendet werden können. 
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ENSG00000141510 TP53 tumor protein p53  Homo sapiens 17 p13.1 
ENSG00000132274 TRIM22 tripartite motif containing 22  Homo sapiens 11 p15.4 
ENSG00000265972 TXNIP thioredoxin interacting protein  Homo sapiens 1 q21.1 
ENSG00000187555 USP7/ 
HAUSP 
ubiquitin specific peptidase 7 
(herpes virus-associated)  
Homo sapiens 16 p13.2 
14-3-2 protein 
family 
YWHA Tyrosine 3-monooxygenase/ 
tryptophan 5-monooxygenase 
activation  
Homo sapiens   
ENSG00000116809 ZBTB17 
MIZ-1 
zinc finger and BTB domain 
containing 17  
Homo sapiens 1 p36.13 
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1 Introduction 
1.1 B-cell development and maturation 
B cells belong to the lymphoid lineage and derive from hematopoietic stem cells (HSC) in the 
bone marrow. They are part of the humoral and cellular adaptive immune system and 
recognize antigens through immunoglobulin (Ig) proteins, that are either bound to the cell 
membrane (as part of the B-cell receptor; BCR) or secreted as antibodies. Ig proteins are highly 
diverse and can be tailored in regard to antigen specificity and immune effector function 
(Figure 1). In early B-cell development the recombination activating genes (RAG1 and RAG2) 
randomly re-arrange segments of the IG gene (variable region, IGV) in a process called V(D)J 
recombination to create various antigen-binding sites1. During maturation, the activation-
induced cytidine deaminase (AID) enzyme mediates class-switch recombination (CSR) and 
somatic hyper-mutation (SHM)2,3. SHM introduces random mutations in the IGV and therefore 
further increases the repertoire of antigen recognition sites. CSR results into exchange of DNA 
fragments of the heavy chain of the IG gene (IGH) and isotype switch from the IgM subtype 
into IgD (as found in the BCR), IgG, IgA or IgD (as found in antibodies). The isotype determines 
the interaction with other immune effector cells.  
  
Figure 1: Genomic rearrangement of immunoglobulin proteins 
Immunoglobulin (Ig) proteins mediate the diverse antigen binding capacity of B cells. They are 
encoded on several gene segments that are combined to a functional gene by two genomic 
rearrangement processes. During V(D)J recombination the RAG complex randomly combines V, 
D and J segments through non-homologous end-joining (NHEJ). The enzyme activation-induced 
cytidine deaminase (AID) adds the constant (C) region leading to class switch recombination 
(CSR). Aberrant NHEJ (A-NHEJ) causes genomic rearrangements (Mani & Chinnaiyan, 2010). 
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Upon T cell-mediated antigen stimulation immature B cells start to proliferate and form 
germinal centers (GC) in peripheral lymphoid organs that are the origin of antibody producing 
plasma cells and memory cells (Figure 2)4,5. GCs consist of two structural subunits: The dark 
zone (DZ), that is densely packed with B cells, and the light zone (LZ), that is additionally 
infiltrated by follicular dendritic cells (FDC), T cells and macrophages4,6. Activated B cells enter 
the DZ where they turn into fast proliferating centroblasts and undergo SHM to create a pool 
of immune cells with various antigen-binding capabilities. Centroblasts suppress cell cycle 
inhibitors and DNA damage response to allow rapid proliferation and mutagenesis, but also 
present with high apoptotic rates5. In addition, reactivated telomerase prevents senescence by 
reconstitution of chromosomal ends, allowing clonal B-cell expansion7. Steered by cytokines, 
centroblasts traffic into the LZ of the GC where they turn into smaller, non-dividing 
centrocytes4. Here, B cells carrying diverse mutations in their IGV gene are exposed to antigens 
and selected for high-affinity binding to pathogenic antigens. Selected B cells either 
differentiate into resting memory cells or undergo CSR to turn into antibody-secreting plasma 
cells. B cells reactive against self-antigens undergo apoptosis. 
 
Figure 2: B-cell maturation in the germinal center 
Antigen-activated immature B cells start to proliferate and form germinal centers (GC). Fast 
proliferating B cells, the centroblasts, form the dark zone of the GC. They are subjected to 
somatic hypermutation (SHM) introducing changes within the variable region of the 
immunoglobulin (IGV) gene to expand the B-cell repertoire. Stimulated by cytokines the cells 
traffic to the light zone of the GC and turn into small, non-dividing centrocytes. After antigen-
affinity selection B cells either differentiate into resting memory B cells or turn into antibody-
secreting plasma cells after class switch recombination (CSR) of their immunoglobulin IGH 
genes (Klein & Dalla-Favera, 2008). 
Introduction 17  
1.2 Aggressive B-cell lymphomas 
GC B cells are prone to malignant transformation. Proliferation, survival and impaired response 
to DNA damage are cancer hallmarks8. Lymphoma cells retain their natural differentiation 
profile9, but errors during genomic modification circumvent failsafe mechanisms of the GC 
reaction4,5. Most B-cell non-Hodgkin lymphomas (B-NHL), including Burkitt lymphoma (BL), 
diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), derive from GC or post-GC 
B cells10,11. Aberrant V(D)J recombination or CSR can activate oncogenes by chromosomal 
translocation to highly active promotor or enhancer regions of IG-loci3,12. Common oncogenes 
that are activated by this mechanism include the anti-apoptotic BCL2 gene in FL13, the cell cycle 
activator CCND1 in mantle cell lymphoma14 and the transcription factor MYC in virtually all BL15 
and about 10% of DLBCL16. Translocation of the transcriptional repressor BCL6, that blocks 
differentiation into plasma cells, is commonly seen in DLBCL17. Aberrant SHM of MYC and 
PRDM1 occurs in 50% of DLBCL18.  
 
Figure 3: Development of aggressive B-cell lymphoma from the germinal center.  
B-cell lymphomas arise at many stages of B-cell development and mostly display signs of GC 
reaction, including mutated IgV genes, chromosomal translocations and aberrant somatic 
hypermutation (ASHM) of cancer associated genes. Burkitt lymphoma (BL) develops from fast 
proliferating centroblasts and acquires MYC-translocations. Diffuse large B-cell lymphoma 
(DLBCL) describes a heterogeneous group of lymphomas. Common genetic aberrations include 
translocations of BCL6 or ASHM of PRMD1 impairing differentiation into plasma cells. NF-kB 
signaling is upregulated in subtypes of DLBCL. Follicular lymphoma (FL) is characterized by 
BCL2 translocations (Klein & Dalla-Favera, 2008). 
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1.3 Burkitt lymphoma 
BL is a mature aggressive B-NHL derived from GC B cells. The WHO classification distinguishes 
three subtypes: Endemic BL (eBL) is associated with Epstein-Barr virus (EBV) and mainly seen in 
malaria-prone regions in equatorial Africa19. Sporadic BL (sBL) mainly occurs in the Western 
World and closely resembles eBL although not linked to infection. A third variant is associated 
with human immunodeficiency virus (HIV-associated BL)20,21. BL is the fastest growing tumor 
with a proliferation index of nearly 100%. The aggressiveness of the disease is driven by 
oncogenic MYC activation and adoption of the transcriptional program of fast-proliferating 
centroblasts. In the last decade molecular and genetic findings greatly improved our 
understanding of BL pathogenesis and extended classical diagnostic criteria.  
1.3.1 Historical review: A “stalking horse” of cancer research 
BL was first described by the clinician Denis Burkitt in 1958 as a jaw tumor in children in 
Uganda22. It was later entitled as the “stalking horse” of cancer23 as it was the first cancer with 
described contribution of viral infection and oncogene activation (by means of chromosomal 
translocation). EBV was first isolated from a BL patient24 and initially thought to be the main 
cause of BL. However, it became apparent later, that EBV is present in 98% of all humans. EBV 
contributes to malignant transformation only in combination with malaria or HIV, when strong 
B-cell cytokine secretion provides pro-survival signals to the pre-malignant B cells25,26. Shortly 
after establishment of chromosomal banding techniques, translocations involving 
chromosomes 8 and 14 were detected in BL27. About 70-80% of cases acquire the translocation 
t(8;14)(q24;q32) which juxtaposes the MYC gene to an IGH-loci and is seen as the hallmark 
lesion in BL. Both variant translocations t(2;8)(p12;q24) and t(8;22)(q24;q11) involving the Ig 
kappa or lambda light chain, respectively, occur at a frequency of about 10%28.  
1.3.2 Epidemiology, clinical and molecular presentation 
eBL mainly occurs in areas with holodemic malaria infection where it accounts for 50% of 
cancers and 90% of lymphomas in children with an incidence of 40-50/million/year (age <18 
years) and a preference in boys29. It presents as swelling of the jaw or periorbital with 
abdominal involvement, but rarely bone marrow (BM) infiltration30. In developed countries sBL 
accounts for 1-5% of B-NHL in adults with an overall incidence of 2.5 cases/million/year and 
30-40% of B-NHL in children with an incidence of 2/million/year31 (Figure 4A). sBL occurs 
bimodal at an age of 3-12 years and in patients aged >60 years32. Childhood and adult sBL 
share a similar gene expression profile33 and therefore seem to depend on the same oncogenic 
pathways although they are often studied separately. Clinical presentation includes rapid cell 
proliferation, BM infiltration (20%), abdominal involvement (60-80%), nodal (mostly in adults) 
and extra-nodal (mostly in children) disease34. Extensive BM infiltration can be a sign of 
development into a leukemic form of BL (acute lymphoblastic leukemia, ALL3). 
Morphologically the cells are medium sized and display with round uncleaved nuclei and 
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basophilic nucleoli and cytoplasm34. All cells are positive for the proliferation marker Ki-67 and 
show a diffuse growth pattern and high apoptotic rate (Figure 4B). Infiltrating macrophages 
engulf apoptotic cells and cause the typically “starry sky” appearance. Immunohistochemistry 
shows markers of B-cell lineage (CD19+, CD20+) and germinal center profile (CD10+, Bcl-6+, 
Bcl-2-) (Figure 4B) (reviewed in Molyneux 2012, Hochberg et al. 2009, Miles et al. 2012). 
 
Figure 4: Incidence and molecular presentation of BL 
(A) Frequency of B-NHL sub-types in children (age 0-14, top) and adults (age >20, bottom). BL 
accounts for about 40% of B-NHL in children and 5% in adults. However, due to the larger age 
span there are more adult BL patients compared to pediatric (modified from Hochberg et al., 
2009). (B) Immunohistochemical features of BL. upper image: The tissue section shows the 
“starry sky” appearance caused by infiltrating macrophages that ingest apoptotic cells. lower 
images: Clinical markers used for BL diagnosis. BL cells are all positive for the proliferation 
marker Ki-67 and express B cell as well as GC markers (CD20+, Bcl-6+, Bcl-2-) (modified from 
Molyneux 2012).  
 
The aggressive growth of BL requires rapid treatment initiation after diagnosis. Treatment 
protocols are mostly based on the FAB LMB study35,36 and include high-dose chemotherapy 
containing methotrexate and cytarabine37. Addition of the monoclonal antibody rituximab has 
greatly improved clinical response (CR) and overall survival (OS) rates38. Remission can be 
achieved in about 90% of children and 70% of adults, but no treatment options are available 
for relapsed patients. The staging of BL is based on the Ann Arbor system in adults and the 
Murphy/St Jude system in children39,40. Poor prognostic markers include age, high LDH levels, 
bone marrow and CNS involvement and failed CR 4-6 month after treatment initiation.  
Ki-67 Bcl-6 
CD20 Bcl-2 
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The diagnosis of BL is mainly based on morphological, cytogenetic and immunophenotypic 
characteristics that are distinctive, but also shared by DLBCL that accounts for 30% of B-NHL in 
adults. An independent review of >200 leukemia and lymphoma patients diagnosed by 
international hematologists showed poor overlap (42%) for patients with intermediate 
phenotype41 that were classified over time as “non-BL”, “Burkitt-like”, “atypical BL” (WHO 
classification 2001) or “B-cell lymphomas unclassifiable with features intermediate between 
DLBCL and BL (BLU)” (WHO classification 2008)19. Distinct gene expression and mutation 
profiles might improve the diagnostic accuracy in the future42-44.  
 
1.3.3 Molecular characterization 
Two microarray studies published at the same time distinguished BL and DLBCL based on their 
molecular gene expression signature (Figure 5)42,43. Both signatures confirmed the pathological 
diagnosis in a subset of “core” BL and re-classified patients displaying with mixed diagnostic 
criteria. Importantly, in the study of Dave et al. patients with a molecular BL (mBL) signature 
that were pathologically diagnosed as DLBCL and treated accordingly with a mixture of 
chemotherapeutic drugs (CHOP - cyclophosphamide, doxorubicin, vincristine, prednisone) had 
significantly inferior outcome. All patients with available data (7/9) died within two years 
whereas 80% of patients treated with intensive regiments, according to BL-specific guidelines, 
were still alive after 10 years of follow-up. Hummel et al. re-defined about 20% of patients 
independent of the IGH-MYC fusion, Bcl-6 or Bcl-2 expression, therefore expanding the 
conventional diagnostic criteria. Low genetic complexity and favorable clinical outcome were 
characteristics of molecular BL. MYC breakpoints in combination with complex karyotype and 
lack of mBL signature were markers for unfavorable clinical outcome.  
The molecular signature also provided insights into pathogenic mechanisms. BL cells expressed 
high level of MYC-targets and typical GC markers, while major histocompatiblity complex 
(MHC) class I and NF-kB targets were low. As shown later, BL is an exception among B-cell 
malignancies as it resembles the transcriptional activation state of centroblasts from the DZ of 
the GC instead of LZ centrocytes9.  
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Figure 5: Gene expression signatures for molecular BL 
For a molecular distinction of BL and DLBCL two independent studies derived gene expression 
signatures based on microarray data. (A) Molecular classification for BL from Dave et al., 2006 
was based on high MYC-target gene expression (stage-1 predictor) and the statistically most 
significant differentially expressed genes compared to DLBCL (stage-2 predictor). (B) Signature 
for molecular BL (mBL) as defined by Hummel et al., 2006. The signature distinguishes mBL 
from DLBCL (non-mBL) and an intermediate group. Genetic complexity is lower in mBL 
compared to non-mBL or intermediates. The core mBL group fulfills all conventional diagnostic 
criteria. 
 
1.3.4 Recurrent copy number alterations in BL 
Translocation of the MYC gene on chr8q24 is a hallmark of BL. Several studies addressed the 
question if additional genetic aberrations contribute to the pathogenesis of this disease or 
classify subgroups. Copy number alterations (CNAs) in BL were studied with increasing 
resolution using conventional cytogenetics45, fluorescent in-situ hybridization (FISH)46, 
comparative genomic hybridization array (CGHa)33,47,48 or single nucleotide polymorphism 
array (SNPa)49-51. About 70% of BL carry secondary structural aberrations and overall genetic 
complexity is lower compared to solid cancer or DLBCL43,49. Comparison of CNAs in pediatric 
and adult BL showed a similar profile, which is in line with the observation that the gene 
expression profile is indistinguishable33,52 (Figure 6A). Discrepant BL and complex BL with MYC 
re-arrangements differ in their cytogenetic profile from mBL33,53 and for comparison across 
cytogenetic studies we have to consider that different criteria were applied to classify the 
patients. Cell lines have in general a more complex karyotype than primary samples47,54,55. 
 The most frequent CNAs are gains of chr1q (40%), and chr13q (10-20%) and loss of chr17p 
(20%) and CNAs were closely correlated to gene expression33,48,49. Despite of the high 
frequency of these aberrations, disease-associated genes often remain elusive. Description of 
candidates is mainly based on highly deregulated cancer consensus genes within minimally 
gained/lost regions. The gain of chr13q31 was linked to the miRNA-17-92 supercluster, a 
transcriptional target of MYC56. miRNAs from this locus prevent apoptosis by downregulation 
of Bim, PTEN or TGFB257-59. Amplification and overexpression is found in solid cancer60 and 
lymphomas where it has been shown to accelerate lymphomagenesis and cooperate with MYC 
in in vivo models59. In pediatric BL gain of chr13q is associated with poor prognosis46,50,52. 
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Chromosome 1q gain is the most frequent CNA in BL and across cancer61. The gained regions 
affect many genes and prediction of cancer drivers is therefore difficult. Amplified segments 
that are consistently reported can be further delineated to 1q25.1 and 1q31.3. The study of 
Salaverria et al. described highly overexpressed cancer-associated genes such as NOTCH2, 
BCL9, PSMB4, MUC1, TXNIP, CKIP-1, ILF2 and CKS1B in the 1cen-q22 region. Scholtysik et al. 
suggested a role for hsa-mir-181b-1 and -213 on chr1q31 and FASL on 1q25, but functional 
validation is needed.  
 
Figure 6: Recurrent copy number alterations in BL 
(A) Profile of recurrent genomic alterations in adult and pediatric BL. Gains on chromosome 1 
are the most frequent alteration apart from the translocation of MYC on chromosome 8 to the 
IgH-locus on chromosome 14 (Onciu et al., 2006). (B) Gained regions on chromosome 1q 
reported in the Mitelman data base (modified from Davidsson et al., 2007). 
 
1.3.5 Oncogenesis  
Pre-malignant B cells frequently adopt transcriptional features from their cell of origin. 
Additional genetic aberrations uncouple the cell from environmental survival and proliferation 
signals10. BL derives and closely resembles centroblasts from the DZ of the GC that are negative 
for MYC62, raising the question at which stage BL cells acquire oncogenic MYC activation. MYC 
expression seems to be limited to a rare population of GC B cells in the LZ that interact with 
antigen-presenting T-helper cells for selection of high-affinity binding63. The translocation of 
MYC to the IgH-locus might be favored by AID-mediated CSR that takes place here18. 
Centrocytes from the LZ can return to the DZ for clonal expansion, a process that is favored by 
MYC expression64. Exposure of the IgH-MYC gene to SHM introduces multiple mutations, some 
of which have been shown to stabilize MYC protein level or to abrogate activation of pro-
apoptotic Bcl2-family member Bim65,66. The GC phenotype and high proliferation rate of BL 
cells is retained by acquisition of activating mutations in the transcription factor E2A (encoded 
by the gene TCF3) or deleterious mutations in its negative inhibitor ID344,67,68. E2A expression is 
higher in centroblasts compared to centrocytes9 and was suggested to increase BCR surface 
expression and PI3K signaling44. E2A also transactivates the cell cycle promoting gene CCND3, a 
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gene that is again frequently targeted by activating mutations44. The tumor suppressor p53 
(encoded by the gene TP53) senses DNA damage and oncogene activation, in part by MYC-
mediated transactivation of ARF. Mutations in TP53 occur in 30-40% of BL patients69. 
Figure 7: Recurrent mutations and oncogenic pathways in BL 
(A) Recurrently mutated genes in BL, GCB DLBCL and ABC DLBCL. In the study of Schmitz et al. 
(2012) RNA sequencing was performed in 28 sporadic BL and 13 BL cell lines. The pattern of 
recurrent mutation was compared to publically available data on mutations in 52 GC DLBCL 
and 28 ABC DLBCL. (B) Schematic overview of key oncogenic signaling pathways in BL with 
indicated contribution of recurrent mutations (Schmitz et al., 2014). 
 
1.3.5.1 Physiological and oncogenic functions of MYC 
The proto-oncogene MYC was first discovered in BL15 and initially called c-MYC (‘c’ for 
‘cellular’) as it closely resembled the myelocytomatosis viral oncogene, v-MYC70. The MYC 
family of nuclear transcription factors includes MYC, N-MYC and L-MYC, three basic helix-loop-
helix (bHLH) leucine zipper proteins that control transcription of its target genes by binding to 
DNA enhancer box sequences (E-boxes) and recruitment of histone acetyltransferases (HATs). 
MYC functions as a transcriptional activator after heterodimerization with MYC-associated 
factor (MAX), and as a repressor of transcription upon binding to Miz-1. Physiologically, MYC 
controls protein biosynthesis, metabolism and cell cycle upon mitogenic signaling leading to an 
increase in cell size before division. MYC transactivates cyclins, cyclin-dependent kinase 4 
(CDK4) and E2F transcription factor and simultaneously represses cyclin-dependent kinase 
inhibitors (CKI) of the Cip/Kip protein family (e.g. p27, p15, p21, p57) and DNA damage induced 
proteins of the GADD family (growth arrest and DNA-damage inducible). The protein MAD1 
(mitotic arrest deficient 1) competes with MYC for the binding of MAX and therefore 
negatively regulates MYC. Under physiological conditions MYC is transcribed from the P2 
promotor, one out of four alternative promotors, resulting into an instable, short-lived protein 
(based on reviews 71-73).  
Deregulated MYC is found across cancers. It is mainly associated with hematological 
malignancies, but also found in carcinomas of the lung, stomach, breast and cervix73. MYC 
functions as an oncogene by stimulatory effects on metabolism and protein synthesis74. The 
oncogenic function of MYC is studied in many cellular and transgenic mouse models. Mice 
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bearing a MYC gene under the highly active IGH enhancer (Eµ-MYC-mice) develop lymphomas 
from both immature and mature B cells75. Simultaneous activation of PI3K and MYC results 
into BL-like tumors displaying a gene expression signature of GC B cells76. BL is commonly used 
as a model to study the pathogenesis of MYC-driven diseases. The translocation of MYC to an 
Ig-locus leads to constitutive transcription from the P1 promotor producing a more stable 
protein that accumulates at high levels in the malignant cell. In addition, MYC is subjected to 
SHM and mutated in 70% of BL. Mutated MYC is a more potent oncogene, although the 
mechanism has only been resolved for selected hotspots within the conserved MYC box I and II 
regions. Tumors arising from MYC-overexpression in Rat1a fibroblasts showed lower apoptotic 
rates when the P138C mutation (box II) was introduced77. Mutations within the conserved MYC 
box I region, mostly on Thr58, stabilize the protein from proteasomal degradation66,78,79. In 
addition, these transactivation domain deficient mutants fail to induce pro-apoptotic Bcl2-
family member Bim and were found to be exclusive to TP53 mutations in one study65.  
 
1.3.5.2 Importance of p53 pathway in BL 
Oncogenic MYC activation triggers p53-dependent apoptosis and senescence as an intrinsic 
safety mechanism80. The transcription factor p53 is a potent tumor suppressor entitled 
“guardian of the genome”81. Upon cellular stress such as DNA damage, hypoxia and oncogene 
activation p53 activates proteins and miRNAs that halt the cell cycle or induces intrinsic 
apoptotic programs. p53 is constitutively expressed, but protein levels are tightly regulated. In 
unstressed cells, the p53 inhibitor MDM2 associates with p53, blocks its transactivation 
domain and targets p53 for proteasomal degradation via its E3 ubiqutin-ligase activity82,83. 
MDM2 itself is a transcriptional target of p53 and activation of p53 therefore induces a 
negative feedback loop. A close homologue of MDM2, MDM4, also blocks the transactivation 
domain of p53, but lacks E3 ubiquitin-ligase activity84. Both proteins are needed for p53 
inactivation. MDM2 forms a heterodimer with MDM4 that is more potent in ubiquitination and 
degradation of p53. However, the E3-ubiquitin ligase activity of MDM2 can be redirected from 
p53 towards MDM4 and self-degradation, based on post-translational protein modifications. 
DNA damage or oncogenic MYC signaling, e.g., activate the p53 pathway by induction of the 
kinase p14ARF (encoded on the CDKN2A locus), that subjects MDM2 for self-degradation85.  
p53 is mutated in 50% of cancers and can be deactivated by alternative mechanisms, such as 
CDKN2A inactivation or MDM2/MDM4 overexpression86. Transgenic Eµ-MYC mice develop 
clonal tumors with delayed onset and high TP53 mutation rate, indicating that secondary 
genetic events, presumably in the p53 pathway, are needed for malignant transformation. In 
fact, TP53 is mutated in 30-40% of BL patients87-89 and 80% of cell lines90,91. Most mutations are 
missense mutations in the core DNA binding domain including the hotspot codons R213, R248 
and less frequently R27388. In contrast to other cancer entities, deletion of the TP53 locus on 
17p13.1 is rare and most TP53 mutations are heterozygous. Mutant p53 exerts a dominant 
negative effect on the wild-type form92. Therefore, monoallelic inactivation leads to a loss of 
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the tumor suppressor function of p5393 and confers radio- and chemoresistance92,94 as shown 
in cell line models. Little is known about the clinical implications of TP53 mutations in BL, 
although the standard therapy is based on chemotherapeutic regiments. In the study of 
Preudhomme et al. (1995) TP53 mutation status did not impact overall survival of 48 BL and 
ALL3 patients. A separate analysis of BL and its leukemic form was not performed.  
Alternative mechanisms to p53 mutations may exist, which inactivate p53 function. Loss of 
CDKN2A in Eµ-MYC mice abrogates apoptosis and accelerates lymphomagenesis95, but rarely 
occurs in BL patients. In some cases promotor methylation was reported for the INK4a 
transcript, but not for ARF 96,97. Mutations of FOXO1 that occur in ~10% of BL patients might 
abrogate the activation of ARF44. MDM2 overexpression, while common in some cancers, is 
absent in BL. In pediatric BL, Leventaki et al. (2014) did not observe MDM2 upregulation, 
however MDM4 mRNA level were elevated in 4 p53 wild-type patients with chromosome 1q32 
gain, including the MDM4 locus. Although an exclusive pattern of CDKN2A deletion, MDM2 
overexpression and TP53 mutations was observed in cell lines98 p53 deactivating mechanisms 
in BL patients are still poorly understood.  
 
1.4 RNAi screens 
Genetic perturbation screens are widely used to understand cellular processes99,100. Two 
naturally occurring mechanisms were exploited as tools to modulate or edit genes of interest: 
RNAi (RNA interference) and CRISPR sequences (clustered regulatory interspaced short 
palindromic repeats). Applications include generation of genetically modified cells or 
organisms and genome-wide positive and negative selection screens for a desired phenotype.  
RNAi is mediated by short interfering RNAs (siRNA) that target complementary mRNA for 
degradation and therefore lead to post-transcriptional gene silencing101. The first silencing 
triggers were long double-stranded RNA (dsRNA) precursors that were introduced into the 
target cell from C. elegans and D. melanogaster102,103. The RNase Dicer cleaves the precursors 
into siRNAs of 21-23 nucleotides (nt) with 2nt 3’-overhang. Upon binding of siRNAs to 
argonaute proteins of the degradation complex RISC (RNA-induced silencing complex) the 
sense strand is degraded and the antisense strand serves as a template to recruit the target 
mRNA104,105. This application was hampered in mammalian organisms by induction of 
interferon (INF) response. Therefore, techniques were developed for direct transfer of 
synthetic siRNAs into mammalian cells leading to transient gene knock-down106. Establishment 
of vector-expressed short-hairpin RNAs (shRNA) that integrate into the genome allowed stable 
gene knock-down107,108. shRNAs are expressed from a RNA polymerase III promoter as ~70nt 
precursors that are processed by Dicer. Initially, retroviral vectors limited the application of 
shRNAs to dividing cells. This was overcome by lentiviral vectors that also integrate into non-
dividing cells109. 
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Establishment of lentiviral, genome-wide shRNA libraries for murine and human genes110,111 
provided a powerful new resource for functional genomics studies. Functional screens are 
performed either in arrayed or pooled format. In arrayed screens cultured cells are seeded out 
on a multi-well plate that contains different silencing triggers in each well. Different 
techniques, including fluorescence, luminescence and imaging can be used as a read-out of 
knock-down phenotypes. With decreasing costs of next-generation sequencing (NGS) pooled 
RNAi screen became an alternative for non-imaging based screens with libraries that integrate 
into the genome. In pooled RNAi screens all silencing triggers are delivered to the cells in one 
flask and genomic DNA is extracted from the cells before and after positive or negative 
selection of the desired phenotype. The abundance of RNA reagents is determined by 
amplification and sequencing of the RNA itself or sequence-optimized vector barcodes. 
In cancer research, RNAi screens were applied to identify pathogenic signaling pathways, 
resistance mechanisms and novel drug targets. The Broad Institute performed a genome-wide 
loss-of-function screen in 216 cell lines across cancer entities with available genetic data and 
identified cancer- and genotype-specific vulnerabilities by loss of shRNAs during 
cultivation112,113.  
RNAi screens are restricted by certain limitations, such as incomplete gene knock-down and 
sequence-specific off-target effects leading to a high false-discovery rate114,115. In a huge effort, 
the RNAi consortium (TRC) from the Broad Institute created a resource of genome-wide shRNA 
libraries for human and murine genes that contains at least two shRNAs with validated on-
target effect111. However, off-target effects are still unpredictable. 
Sequence-guided endonucleases emerged as a novel technology for genetic perturbation 
screens and targeted genomic engineering116. The system exploits the microbial adaptive 
immune system in response to viral infection117-119 and endogenous DNA repair mechanisms of 
eukaryotic cells120,121. Endonucleases directed against a target sequence introduce double-
strand breaks (DSB). In the presence of an exogenous DNA template DSBs are repaired 
precisely by homology-directed repair (HDR)122. This mechanism can be exploited to repair 
mutations in malignant cell or to intentionally introduce mutations in model organisms to 
study their pathogenic function123. In the absence of DNA template DSBs are repaired by the 
error-prone non-homologous end joining (NHEJ) resulting into random insertions and deletions 
(indels) and therefore disrupts the gene124. A common system from Streptococcus pyrogenes 
involves endonuclease Cas9 which is directed to a target sequence by 20bp single guide RNAs 
(sgRNAs) that pair with a complementary sequence in the DNA followed by a 3bp PAM 
(protospacer-adjacent motif) sequence125. Genome-wide sgRNA libraries are already in use for 
in vitro and in vivo screens and might be potential therapeutic tools for gene therapy126,127.  
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Figure 8: Functional genomics approaches 
(A) Schematic overview of RNA interference (RNAi). Sequence complementary short hairpin 
RNAs (shRNAs), small interfering RNAs (siRNAs) or long double-stranded RNAs (dsRNAs) are 
introduced into the cell to target specific mRNA for degradation. shRNAs stable integrate into 
the genome while siRNAs and long dsRNAs are introduced transiently. After binding to the 
RNA-induced silencing complex (RISC) the sense strand is degraded and the antisense strand 
binds with complementary mRNA sequences and induces cleavage. (B) Genomic engineering 
and perturbation using the CRISPR/Cas9 technology. Directed by a guide RNA the bacterial 
endonuclease Cas9 unwinds the DNA strand next to the protospacer-adjacent motif (PAM) and 
induces double strand breaks. Error-prone non-homologous end-joining induces deletions and 
insertions leading to impaired gene function. (C) Schematic overview of arrayed (left) and 
pooled (right) genetic perturbation screens. In arrayed screens, RNA reagents are delivered to 
cells in single well format either by transduction (shRNAs) or by transfection (siRNAs). In 
pooled screens, RNA reagents are mixed in one tube, packaged in lentiviral particles and 
delivered to the bulk of cells at low infection rates to avoid infection with multiple vectors. The 
pool of cells is separated into different treatment branches and barcodes are read out by next-
generation sequencing (modified from Shalem et al., 2015). 
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2 Scientific Aims  
Burkitt lymphoma (BL) is a highly proliferative B-cell lymphoma that arises from the germinal 
center during B-cell maturation. Oncogenic activation of MYC drives cell proliferation, but also 
evokes failsafe mechanisms that have to be counterbalanced. Mutations in the tumor 
suppressor gene TP53 convey resistance towards MYC-induced stress signals, but alternative 
mechanisms of evading apoptotic programs are unknown. 
Aim of this study was to identify alternative mechanisms of p53 inactivation in BL retaining a 
functional TP53 gene. We addressed the following points: 
1. Pattern of recurrent mutations in BL  
We analyzed the pattern of frequent mutations and copy number alterations for co-
occurrence and exclusivity with TP53 mutations to see if we can identify divergent 
mechanisms to deregulate this pathway.  
 
2. Genetic vulnerabilities in BL cell lines 
To identify genes essential in the presence of functional p53, we explored the robustness 
and sensitivity of a RNAi loss-of-functionl screen in genetically defined cell line models. 
 
3. Functional mechanisms underlying genotype-specific vulnerabilities 
To explore the molecular mechanisms of genotype-specific toxicities observed in the RNAi 
screen, we characterized downstream effects following shRNA-mediated knock-down of 
genes essential in p53 wild-type BL cell lines using cell cycle profiling, immunoblot analysis 
and micro-array based gene expression profiling. 
 
4. Potential of p53 reactivating therapies 
To test if genes that were found to be essential specifically in p53 wild-type BL are 
potential therapeutic targets, we measured the effect of target gene knock-down on p53 
reactivation, cell growth and tumor formation in vivo. 
 
5. Clinical importance of p53 inactivation in BL  
To evaluate the role of potential target genes in the pathogenesis of BL patients, we 
integrated our findings from the RNAi screen with molecular and genetic patient profiles.  
 
6. RNAi screens for identification of entity-specific vulnerabilities 
We further explored the potential of genetic perturbation screens across cancer cell lines 
for identification of novel therapeutic targets in a specific cellular context, such as cell 
lineage or gene mutation. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 List of materials  
Reagent Company 
Cell culture 
Dulbecco's Modified Eagle Medium (DMEM) Thermo Fisher Scientific, Waltham, USA 
RPMI medium 1640 Thermo Fisher Scientific, Waltham, USA 
Foetal Bovine Serum Premium, South America PAN-Biotech, Aidenbach, GER 
Foetal Bovine Serum Thermo Fisher Scientific, Waltham, USA 
L-Glutamine, 200mM Thermo Fisher Scientific, Waltham, USA 
Penicillin-Streptomycin Solution (100x, 1:1) Thermo Fisher Scientific, Waltham, USA 
Dulbecco's PBS without Ca/Mg (1X) Thermo Fisher Scientific, Waltham, USA 
Trypan Blue Staining solution 0.4% Thermo Fisher Scientific, Waltham, USA 
Dimethyl sulfoxide (DMSO), ≥95% Sigma-Aldrich, Munich, GER 
FastRead 102 Disposable counting chambers Immune systems, Paignton, UK 
Lentiviral packaging, infection and selection 
Opti-MEM® I reduced serum medium Thermo Fisher Scientific, Waltham, USA 
Lipofectamine® Transfection Reagent Thermo Fisher Scientific, Waltham, USA 
PLUS
TM
 Reagent Thermo Fisher Scientific, Waltham, USA 
Puromycin Dihydrocloride Thermo Fisher Scientific, Waltham, USA 
RNAi screen 
shRNA library Human Module 1, DHPAC-M1-P Cellecta Inc., Mountain View, CA, USA 
Buffer P1 (50mM Tris-HCl pH 8.0, 10mM EDTA) Qiagen, Hilden, GER 
RNase A (17,500U) Qiagen, Hilden, GER 
Phenol:Chloroform:Isoamyl Alcohol pH 8.0 Sigma-Aldrich, Munich, GER 
DNase I, RNase-free Epicentre, Madison, WI, USA 
Titanium Taq DNA polymerase with PCR buffer Takara Bio Europe, St-Germain-en-Laye, FR 
Magnesium chloride Sigma-Aldrich, Munich, GER 
PCR 
Taq DNA Polymerase  Qiagen, Hilden, GER 
Taq Polymerase S (high specificity) Genaxxon, Ulm, GER 
dNTP-Set (Na-salt) - 100 mM Genaxxon, Ulm, GER 
100bp DNA ladder  Thermo Fisher Scientific, Waltham, USA 
1 Kb DNA ladder Thermo Fisher Scientific, Waltham, USA 
Agarose for DNA electrophoresis Serva Electrophoresis, Heidelberg, GER 
Agencourt AMPure XP Beckman Coulter, Krefeld, GER 
QIAquick PCR Purification Kit Qiagen, Hilden, GER 
DNA vector cloning 
One Shot® TOP10 Chemically Competent E.coli Thermo Fisher Scientific, Waltham, USA 
XL10-Gold Ultracompetent Cells Agilent Technologies, Böblingen, GER 
Ampicillin sodium salt Sigma-Aldrich, Munich, GER 
Spectinomycin Sigma-Aldrich, Munich, GER 
Agar powder Sigma-Aldrich, Munich, GER 
Luria Broth Base (LB) powder Thermo Fisher Scientific, Waltham, USA 
S.O.C Medium Thermo Fisher Scientific, Waltham, USA 
Bpil (BbsI) Thermo Fisher Scientific, Waltham, USA 
Buffer G Thermo Fisher Scientific, Waltham, USA 
BsmBI Thermo Fisher Scientific, Waltham, USA 
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Reagent Company 
BamHI NEB, Ipswitch, MA, USA 
SfbI NEB, Ipswitch, MA, USA 
T4 Polynucleotide Kinase incl. 10x buffer NEB, Ipswitch, MA, USA 
T4 DNA Ligase NEB, Ipswitch, MA, USA 
rATP 100mM solution GE Healthcare, Frankfurt, GER 
GeneMatrix Plasmid MiniPrep DNA Purification Kit  EURx, Gdansk, PL 
EndoFree Plasmid Maxi Kit Qiagen, Hilden, GER 
QuickExtract DNA Extraction solution  Epicentre, Madison, WI, USA 
Plasmid Giga Kit  Qiagen, Hilden, GER 
QIAquick Gel Extraction Kit Qiagen, Hilden, GER 
T7 Endonuklease I NEB, Ipswitch, MA, USA 
DNA and RNA purification/quantification 
DNeasy Blood & Tissue Kit Qiagen, Hilden, GER 
RNeasy Mini Kit  Qiagen, Hilden, GER 
Quant-it™ PicoGreen® dsDNA Assay Kit Thermo Fisher Scientific, Waltham, USA 
Qubit® dsDNA BR Assay Kit Thermo Fisher Scientific, Waltham, USA 
Qubit® RNA BR Assay Kit Thermo Fisher Scientific, Waltham, USA 
Qubit® Assay Tubes Thermo Fisher Scientific, Waltham, USA 
QIAshredder columns Qiagen, Hilden, GER 
RNAse Away™ Ambion GmbH, Kassel, GER 
RiboLock RNase Inhibitor Thermo Fisher Scientific, Waltham, USA 
RNase-Free DNase Set Qiagen, Hilden, GER 
DNA and RNA sequencing 
SUPREMERUN™ sequencing GATC Biotech AG, Konstanz, GER 
twin.tec® PCR plate 96 Eppendorf, Hamburg, GER 
GS Junior Titanium emPCR Kit (Lib-A) Roche, Basel, CH 
GS Junior Titanium Sequencing Kit Roche, Basel, CH 
GS Junior Maintenance Wash Kit Roche, Basel, CH 
RT-qPCR 
QuantiFast SYBR Green RT-PCR Kit Qiagen, Hilden, GER 
Western Blot 
Skimmed milk powder Carl Roth GmbH&Co, Karlsruhe, GER 
BSA Protease Free PAA, Cambridge, UK 
Tween® 20 Sigma-Aldrich, Munich, GER 
Tris buffer pH 7.5 (1 M) AppliChem Inc., Maryland Heights MO, USA 
Sodium chloride (NaCl) Sigma-Aldrich, Munich, GER 
Kalium chloride (KCl) Carl Roth GmbH&Co, Karlsruhe, GER 
10x RIPA Lysis Buffer Merck/Millipore, Darmstadt, GER 
Benzonase® Merck/Millipore, Darmstadt, GER 
Pierce™ BCA Protein Assay Kit Thermo Fisher Scientific, Waltham, USA 
Pierce™ Bovine Serum Albumin Standard Ampules, 
2 mg/ml 
Thermo Fisher Scientific, Waltham, USA 
PhosSTOP (phosphatase inhibitor cocktail) Roche Life Science, Indianapolis, IN, USA 
cOmplete™, EDTA-free Protease Inhibitor Sigma-Aldrich, Munich, GER 
Laemmli sample buffer, 2x concentrate Sigma-Aldrich, Munich, GER 
Mini-PROTEAN® TGX™ Precast Gels 4-15% BioRad, Munich, GER 
10x Tris/Glycine/SDS Running buffer BioRad, Munich, GER 
PageRuler™ Prestained Protein Ladder Thermo Fisher Scientific, Waltham, USA 
Trans-Blot® Turbo™ RTA Mini LF PVDF Transfer Kit BioRad, Munich, GER 
Fluorescence and luminescence assays 
CellTiter-Glo® Luminescent Cell Viability Assay Promega GmbH, Mannheim, GER 
Annexin V, APC BD Biosciences, San Jose, CA, USA 
Annexin V Binding Buffer, 10x Concentrate BD Biosciences, San Jose, CA, USA 
7-AAD (7-Aminoactinomycin) BD Biosciences, San Jose, CA, USA 
Propidium iodide ≥94% HPLC Sigma-Aldrich, Munich, GER 
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Reagent Company 
FISH probes XL 1p32 / 1q21 (D-5049-100-OG) MetaSystems GmbH, Altlussheim, GER 
FISH probes XT MYC BA (D-6023-100-OG) MetaSystems GmbH, Altlussheim, GER 
BREATH-EASY sealing membrane Sigma-Aldrich, Munich, GER 
BD Pharmingen™ APC BrdU Flow Kit BD Biosciences, San Jose, CA, USA 
Formaldehyd, 30% Carl Roth GmbH&Co, Karlsruhe, GER 
FIX/PERM® Solution B Nordic MUbio, Susteren, NL 
Chemicals 
Ethanol absolute Sigma-Aldrich, Munich, GER 
Methanol Sigma-Aldrich, Munich, GER 
Isopropanol Sigma-Aldrich, Munich, GER 
Nutlin-3 Absource Diagnostics, Munich, GER 
3.1.2 List of instruments and devices 
Instruments and devices Company 
Sonopuls ultrasonic homogenizer Bandelin, Berlin, GER 
Flow Cytometer LSR Fortessa
™ 
 BD Biosciences, San Jose, CA, USA 
Flow Cytometer LSRII™  BD Biosciences, San Jose, CA, USA 
Flow Cytometer FACSAria™ Cell Sorter BD Biosciences, San Jose, CA, USA 
Cobas® z480 Analyzer Roche, Basel, CH 
Mini-PROTEAN® Tetra Vertical Electrophoresis Cell  BioRad, Munich, GER 
Trans-Blot® Turbo™ Transfer System BioRad, Munich, GER 
Fluorescence scanner Odyssey®  Li-cor, Lincoln, NE, USA 
Microplate reader Infinite® M1000 PRO Tecan AG, Männedorf, CH 
Thermocycler Biometra, Göttingen, GER 
peqSTAR 96X Thermocycler PeqLab/VWR, Erlangen, GER 
GS Junior 454 sequencer Roche, Basel, CH 
NanoDrop® Spectrophotometer ND-1000 PeqLab/VWR, Erlangen, GER 
PerfectBlue Gel system PeqLab/VWR, Erlangen, GER 
Liberty 120 rapid gel system Neuvitro Corp., Vancouver, WA, USA 
HighSeq 2000 genome sequencer Illumina, San Diego, CA, USA 
Qubit 2.0 Fluorometer Thermo Fisher Scientific, Waltham, USA 
Bioanalyzer 2100 Agilent Technologies, Böblingen, GER 
3.1.3 List of software and operating systems 
Software/Operating system Company/Institution 
Barcode Deconvoluter software Cellecta Inc., Mountain View, CA, USA 
Python™ v2.7.10 Python, San Francisco, CA, USA 
R v3 and above R, open source 
R Studio™ R Studio, Boston, MA, USA 
GENE-E v3.0.204 (for academic use) Broad Institute, Boston, MA, USA 
GSEA Broad Institute, Boston, MA, USA 
LightCycler 480 Software release 1.5.0  Roche, Basel, CH 
Odyssey operation software v3 Li-cor, Lincoln, NE, USA 
GraphPad Prism v5.03 GraphPad Software, La Jolla, CA, USA 
GS Junior Sequencer v2.5 Roche, Basel, CH 
GS Amplicon Variant Analyzer v2.5 Roche, Basel, CH 
Image Studio Lite v4.0 Li-cor, Lincoln, NE, USA 
FlowJo v10 FlowJo, Ashland, OR, USA 
FACSDiva™ Software v6/8.1 BD Biosciences, San Jose, CA, USA 
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3.1.4 List of oligo-nucleotides 
RNAi screen 
Name Sequence [5'-3'] Reaction 
FwdHTS TTCTCTGGCAAGCAAAAGACGGCATA 1
st
 Round PCR 
RevHTS1 TAGCCAACGCATCGCACAAGCCA 1
st
 Round PCR 
FwdGex CAAGCAGAAGACGGCATACGAGA 2
nd
 Round PCR  
RevGex AATGATACGGCGACCACCGAGA 2
nd
 Round PCR  
IndA AATGATACGGCGACCACCGAGATCTACACGCAATGCGCACAACCGCAA Multiplexing 
IndB AATGATACGGCGACCACCGAGATCTACACGCAGACTGCACAACCGCAA Multiplexing 
IndC AATGATACGGCGACCACCGAGATCTACACGCATCAGGCACAACCGCAA Multiplexing 
IndD AATGATACGGCGACCACCGAGATCTACACGCACGTAGCACAACCGCAA Multiplexing 
IndE AATGATACGGCGACCACCGAGATCTACACGCAAGCGGCACAACCGCAA Multiplexing 
IndF AATGATACGGCGACCACCGAGATCTACACGCAGATGGCACAACCGCAA Multiplexing 
IndG AATGATACGGCGACCACCGAGATCTACACGCAGGACGCACAACCGCAA Multiplexing 
IndH AATGATACGGCGACCACCGAGATCTACACGCAGCGAGCACAACCGCAA Multiplexing 
GexSeqS AGAGGTTCAGAGTTCTACAGTCCGAA 
Barcode 
sequencing 
GexSeqIND ACGACCACCGAGATCTACACGCA Indexing 
HPLC purified oligo-nucleotides were ordered at MWG Eurofins (Ebersberg, GER). 
 
RT-qPCR 
Name Sequence [5'-3'] Source 
qMDM4_fwd TGAAAGACCCAAGCCCTCT Self-designed 
qMDM4_rev CGAGAGTCTGAGCAGCATCTG Self-designed 
qTP53_fwd GGAGCACTAAGCGAGCACTG Self-designed 
qTP53_rev CACGGATCTGAAGGGTGAAA Self-designed 
qMDM2_fwd CAGTAGCAGTGAATCTACAGGGA RT-Primer Bank 
qMDM2_rev CTGATCCAACCAATCACCTGAAT RT-Primer Bank 
qBAX_fwd CCCGAGAGGTCTTTTTCCGAG RT-Primer Bank 
qBAX_rev CCAGCCCATGATGGTTCTGAT RT-Primer Bank 
qRRM2B_fwd AGAGGCTCGCTGTTTCTATGG RT-Primer Bank 
qRRM2B_rev GCAAGGCCCAATCTGCTTTTT RT-Primer Bank 
qCDKN1A_fwd GACTCTCAGGGTCGAAAACG self-designed 
qCDKN1A_rev TAGGGCTTCCTCTTGGAGAA self-designed 
qMCM7_fwd CCTACCAGCCGATCCAGTCT RT-Primer Bank 
qMCM7_rev CCTCCTGAGCGGTTGGTTT RT-Primer Bank 
qMCM6_fwd ACCTGCCTACCAGACACAAGA RT-Primer Bank 
qMCM6_rev ACAGAAAAGTTCCGCTCACAAG RT-Primer Bank 
qMCM10_fwd TGTCCCTGCGCTACCAAGA RT-Primer Bank 
qMCM10_rev GATGAGCTTTTGGGATCTGGAG RT-Primer Bank 
qCDKN3_fwd TCCGGGGCAATACAGACCAT RT-Primer Bank 
qCDKN3_rev GCAGCTAATTTGTCCCGAAACTC RT-Primer Bank 
qGAPDH_fwd GGAGCGAGATCCCTCCAAAAT RT-Primer Bank 
qGAPDH_rev GGCTGTTGTCATACTTCTCATGG RT-Primer Bank 
HPSF purified oligo-nucleotides were ordered at MWG Eurofins (Ebersberg, GER). 
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shRNA target sequences 
Name Sequence [5'-3'] Cellecta shRNA ID 
CDKN3_1 CGGGACAAATTAGCTGCACAT CLL-H-005488 
CDKN3_2 TGTTCTCAGTTTCTCGGTTTA CLL-H-005489 
CDKN3_3 CAGACCATCAAGCAATACAAT CLL-H-005490 
CDKN3_4 AGAACTAAAGAGCTGTGGTAT CLL-H-005491 
CDKN3_5 GTGCAGATATTCCTAAAGTTT CLL-H-005492 
CDKN3_6 GACCATGTCTGAAATGTCAGT CLL-H-005493 
MDM2_1 CTTTGGTAGTGGAATAGTGAA CLL-H-016687 
MDM2_2 GATTCCAGAGAGTCATGTGTT CLL-H-016688 
MDM2_3 CGATTATATGATGAGAAGCAA CLL-H-016689 
MDM2_4 CTGTGTGTAATAAGGGAGATA CLL-H-016690 
MDM2_5 CTCAGCCATCAACTTCTAGTA CLL-H-016691 
MDM4_4 CACCTAGAAGTAATGGCTCAA CLL-H-016692 
MDM4_1 GTTCACTGTTAAAGAGGTCAT CLL-H-016693 
MDM4_7 CCCTGATTGTCGAAGAACCAT CLL-H-016694 
MDM4_5 ACAGTCCTTCAGCTATTTCAT CLL-H-016695 
MDM4_6 CTCAACTGATTTACAGACAAA CLL-H-016696 
shNT CAACAAGATGAAGAGCACCAA   
Design of single-stranded shRNA oligo-nucleotides for cloning into an expression vector is 
described in chapter 3.4.4. Desalted oligonucleotides were ordered at Sigma-Aldrich (Munich, 
GER).  
 
sgRNA target sequences 
Name Sequence [5'-3'] Source 
TP53_3 CATGTGTAACAGTTCCTGCA Shalem et al., 2014 
TP53_7 GAGCGCTGCTCAGATAGCGA HGLibB_51984 
TP53_8 CCCCTTGCCGTCCCAAGCAA HGLibB_51985 
Design of single-stranded sgRNA oligo-nucleotides for cloning into an expression vector is 
described in chapter 3.4.4. Desalted oligo-nucleotides were ordered at Sigma-Aldrich (Munich, 
GER).  
 
PCR primer 
Name Sequence [5'-3'] 
TP53_ex4a_fwd TGACTGCTCTTTTCACCCATCT 
TP53_ex4a_rev GAAGATGACAGGGGCCAG 
TP53_ex4b_fwd CCTGCACCAGCAGCTCCTAC 
TP53_ex4b_rev CAGGCATTGAAGTCTCATGGA 
TP53_ex5_fwd CAACTCTGTCTCCTTCCTCTTCC 
TP53_ex5_rev GTCGTCTCTCCAGCCCCA 
TP53_ex6_fwd GAGAGACGACAGGGCTGGTT 
TP53_ex6_rev CTTAACCCCTCCTCCCAGAG 
TP53_ex7_fwd CTTGGGCCTGTGTTATCTCC 
TP53_ex7_rev GAGGTGGATGGGTAGTAGTATGG 
TP53_ex8_fwd GCTTCTCTTTTCCTATCCTGAGT 
TP53_ex8_rev GCTTCTTGTCCTGCTTGCT 
TP53_ex9_fwd GTGCAGTTATGCCTCAGATTC 
TP53_ex9_rev CAGTCAAGAAGAAAACGGCAT 
TP53_ex10_fwd GCATGTTGCTTTTGTACCGTC 
TP53_ex10_rev GGAAGGGGCTGAGGTCACT 
MYD88_ex5_fwd GCATGTGTGTGCCTTTTTGT 
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Name Sequence [5'-3'] 
MYD88_ex5_rev GATGAACCTCAGGATGCTGG 
sgTP53_8_fwd TTCCTGAAAACAACGTTCTGg 
sgTP53_8_rev GGTGTAGGAGCTGCTGGTG 
LCIII_fwd AGTGGCACAGCAGTTAGG 
LTR IV_rev CCTTGCAAAATGGCGTTACT 
pRSI12 Colony PCR_fwd AAAGTATTTCGATTTCTTGGCTTT 
pRSI12 sequencing CAAGGCTGTTAGAGAGATAATTGGAA 
pLentiCRISPRv2 sequencing GTACAAAATACGTGACG 
HPLC-purified oligo-nucleotides were ordered at MWG Eurofins. For multiplexed 454 
sequencing LCIII sequence was added to forward primers and LTR IV sequence was added to 
the reverse primers to add universal tails to the PCR products (see chapter 3.4.2). 
3.1.5 List of plasmids 
Name Promoter Genes Function Source 
pMD2.G CMV VSV-G Lentiviral packaging Michael Böttcher (DKFZ) 
psPAX2 CAG gag, pol, rev, Lentiviral packaging Michael Böttcher (DKFZ) 
pRSI12 U6 TagRFP, puroR shRNA expression Cellecta Inc. 
pLentiCRISPR v2 SV40 puroR, Cas9-FLAG sgRNA expression 
Feng Zhang  
(Addgene # 52961) 
3.1.6 List of antibodies 
Gene MW[kDa] Company Clone Cat. no. Host  Dilution  
MDM4 80 Merck-Millipore 8C6 04-1555 mouse 1:1000 
MDM2 75 Merck-Millipore IF2 OP46 mouse 1:50 
GAPDH 37 Abcam pAb ab9485 rabbit 1:2500 
p53-FITC  53 BD Pharmingen™ DO-1 557026 mouse 1:25 
p53 53 BD Pharmingen™ DO-7 554294 mouse 1:5000 
p21 21 BD Pharmingen™ SXM30 556431 mouse 1:250 
PUMA 24 SantaCruz pAb sc-28226 rabbit 1:100 
cleaved PARP 89 Cell Signaling pAb 9546 mouse 1:1000 
Anti-mouse  Cell Signaling DyLight 800 5257 goat 1:15,000 
Anti-rabbit  Cell Signaling DyLight 680 5366 goat 1:15,000 
MW = molecular weight pAb = polyclonal antibody 
3.1.7 List of web and data resources 
Name Website 
NCBI National Center for Biotechnology Information, Rockville , Bethesda MD, USA 
(www.ncbi.nlm.nih.gov) 
Ensembl Wellcome Trust Sanger Institute, Hinxton, UK (www.ensembl.org) 
UCSC UC Santa Cruz, California, USA (genome.ucsc.edu) 
COSMIC Wellcome Trust Sanger Institute, Hinxton, UK (cancer.sanger.ac.uk/cosmic) 
TP53 Database IARC, Lyon, France (p53.iarc.fr) 
GENE-E Broad Institute, Boston, USA (broadinstitute.org/cancer/software/GENE-E) 
GSEA Broad Institute, Boston, USA (broadinstitute.org/gsea/index.jsp ) 
Gene Pattern Broad Institute, Boston, USA (broadinstitute.org/cancer/software/genepattern) 
DSMZ Leibniz Institute, Braunschweig, GER (dsmz.de) 
cBio Portal Memorial Sloan-Kettering Cancer Center, New York, USA (cbioportal.org) 
RT Primer bank https://pga.mgh.harvard.edu/primerbank/ 
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3.1.8 List of laboratory services 
Method Company/Institution 
Capillary sequencing (ABI 3730xl) GATC Biotech, Konstanz, GER 
Next-generation sequencing 
(Illumina HiSeq2000) 
DKFZ genomics and proteomics core facility 
Gene expression profiling 
(Illumina BeadChip HumanHT-12 v4) 
DKFZ genomics and proteomics core facility 
Gateway Full ORF clone DKFZ genomics and proteomics core facility 
Cell line authentification Multiplexion, Heidelberg, GER 
Cell line contamination test Multiplexion, Heidelberg, GER 
FISH analysis  Prof. Dr. Anna Jauch, University Hospital Heidelberg, 
Institute of Human Genetics 
MYC box mutation analysis Heiko Trautmann (University Hospital Schleswig-Holstein) 
EBV status analysis Prof. Dr. Henri-Jacques Delecluse, DKFZ 
  
3.2 Primary sample analysis 
Data on primary samples from lymphoma patients were generated within the network of the 
MMML (Molecular Mechanisms of Malignant Lymphoma) consortium, that was founded in 
2003. The data set was finalized in 2011. The study was approved by the local ethics 
commission of the Georg-August University in Göttingen, Germany. The data is available at the 
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) under the accession numbers 
GSE43677 (for microarray data) and GSE21597 (for SNP array data). Sample processing and 
generation of micorarray data were described previously43,49,128. All bioinformatic analyses on 
primary patient material in this study were performed in cooperation with Maciej Rosolowski 
and Markus Kreuz (Institute of Medical Informatics, Statistics and Epidemiology (IMISE), 
University of Leipzig, Leipzig, GER). Patients were classified into BL, DLBCL and an intermediate 
group based on a previously described molecular signature43. Tumor cell content exceeded 
70% in all cases.  
DNA was extracted using reagents from Qiagen (Hilden, GER). Copy number variations were 
analyzed by CGHa using a BAC/PAC array that consisted of 2799 DNA fragments as described 
elsewhere129,130. Interphase FISH analysis was performed on paraffin-embedded or frozen 
tissue sections to determine MYC, BCL2 and BCL6 translocations to IG enhancer regions.  
TP53 mutations were determined by sequencing of exons 4-10 of the coding region. 
For gene expression analysis, RNA was extracted using reagents from Qiagen (Hilden, GER) and 
hybridized to an Affymetrix U133A GeneChip (Santa Clara, CA, USA) according to the 
manufacturer´s instructions using 5µg of total RNA. For analysis of the most differentially 
expressed genes in TP53mut and TP53wt B-NHL, all values were adjusted for subtype-specific 
effects. 
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3.3 Cell culture methods 
3.3.1 List of cell lines 
Name Depositor  Name Depositor 
BJAB DSMZ, Braunschweig, Germany  DG-75 DSMZ, Braunschweig, Germany 
BL-2 DSMZ, Braunschweig, Germany  Gumbus DSMZ, Braunschweig, Germany 
CA46 DSMZ, Braunschweig, Germany  BL7 Dr.G.M. Lenoir, IARC, Lyon, France 
Namalwa DSMZ, Braunschweig, Germany  BL60 Dr.G.M. Lenoir, IARC, Lyon, France 
Ramos DSMZ, Braunschweig, Germany  LY47 Dr.G.M. Lenoir, IARC, Lyon, France 
Raji DSMZ, Braunschweig, Germany  Salina A. Rickinson, Birmingham, UK 
BL-41 DSMZ, Braunschweig, Germany  Seraphine A. Rickinson, Birmingham, UK 
DogKit DSMZ, Braunschweig, Germany  Cheptanges A. Rickinson, Birmingham, UK 
HEK293T Stefan Fröhling (DKFZ)    
 
3.3.2 Cell line cultivation, quality control and cryopreservation 
All cell lines were cultured under standard conditions (37°C, 5% CO2). Lymphoma cell lines 
were cultured in RPMI and HEK293T cells in DMEM supplemented with 10% FBS (20% for 
Cheptanges, BL7, Gumbus, DogKit), 2mM fresh glutamine and 1% penicillin/streptomycin. For 
cell line authentication 200ng genomic DNA were submitted to Multiplexion (Heidelberg, GER) 
for single nucleotide polymorphism (SNP)-profiling. To test for contamination, cell extracts 
were prepared from ~2x106 cells by heating for 15min at 95°C. After removal of cell debris by 
centrifugation, the supernatant was submitted to Multiplexion for multiplex PCR analysis of 
100 contaminants, including 14 mycoplasma strains, EBV, Squirrel Monkey Retrovirus (SMRV) 
and cross-species cell contaminations. For cryopreservation, cells were frozen in liquid 
nitrogen at 3-5x106 cells/ml in the respective cell culture medium containing 30% FBS and 10% 
DMSO. Cell vials were stored in Mr. Frosty freezing containers (Thermo Fisher Scientific, 
Schwerte, GER) at -80°C for gradual cool down over 24h. 
3.3.3 Cell line characterization 
TP53 mutation status was determined by targeted resequencing of exons 4-10 (see 3.4.2). MYC 
box I and II mutations were determined by Dr. Heiko Trautmann and Dr. Christiane Pott 
(University Hospital Schleswig-Holstein, Kiel, GER) using Sanger sequencing. Genetic 
aberrations of chromosome 1q or MYC were reported by the DSMZ cell line bank or the CGHa 
study from Toujani et al., (2009). In cases with missing data we determined MYC breakpoints 
or chr1q21 rearrangements by FISH using the MYC break apart probe and 1p32/1q21, 
respectively (performed by Dr. Anna Jauch at the Institute of Human Genetics, University 
Hospital Heidelberg, GER). EBV-status was tested by protein staining for EBNA2 (expressed 
during latency III) and BHRF1 (expressed in Wp-restricted cell lines) (performed in the 
laboratory of Prof. Delecluse, DKFZ, Heidelberg, GER). 
3.3.4 Lentiviral packaging 
For lentiviral packaging, HEK293T/17 cells were used, a derivative of the HEK293 cell line that 
was established from transformed human embryonic kidney cells. HEK293T/17 expresses 
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Simian Virus-40 (SV-40) T-antigen that allows episomal replication of transfected plasmids and 
therefore prolongs the effective production of lentiviral particles. The cell line was derived 
from a single cell clone that was selected for high transfection rates. Cells were seeded out at a 
density of 2.5x105 cells/ml. After 24h of cultivation cells were growing adherent again and 
were transfected with three plasmids: the target transfer vector, the envelope vector 
(pMD2.G) and the packaging plasmid of the 2nd generation (psPAX2). According to the table 
below, a packaging-plus and a lipofectamine mix were prepared. The packaging-plus mix was 
incubated for 15min at RT, gently mixed with the lipofectamine mix and again incubated for 
15min at RT. The complexed molecules were added to the medium of the HEK293T/17 cells by 
gentle pipetting and mixed by slow rotation of the plate. After growing the cells for 12-18h in 
the presence of the transfection mix the medium was replaced and virus-producing cells were 
cultivated for 24h-36h. Transfection efficiency was estimated based on RFP expression 
observed in fluorescence microscopy. The supernatant of the HEK293T/17 cells was filtered 
through a 45µM filter and stored at -80°C. 
  Per well In 6-well [µl] In 10cm dish [µl] 
Packaging-plus mix per shRNA 
OPTI-MEM 190µl 190          950  
PACKAGING MIX psPAX2: 
pMD2.G, 2:1, 500ng/µl 
820ng : 410ng 2.5            13  
Plus-Reagent 2.5µl 2.5            13  
Target plasmid, 50ng/µl 250ng 5            25  
Lipofectamine mix 
Opti-MEM 197µl 197          985  
Lipofectamine 3.7µl 3.7            19  
Add Mix to the well/dish   401      2,004  
3.3.5 Lentiviral infection  
BL cell lines were seeded out at a final cell density of 5x105 cells/ml. Lentiviral supernatant was 
added to the cell culture according to previously determined virus titer to achieve desired 
infection rates. Polybrene is commonly used to increase lentiviral infection rates. However, in 
BL cell lines polybrene was toxic at low concentrations and no beneficial effect on infection 
rate was observed. 
3.3.6 Puromycin titration and selection 
Puromycin was used to select transduced cells that carried a puromycin resistance gene as a 
selection marker. The optimal concentration of puromycin was titrated on each cell line. Cells 
were cultivated for 24h or 48h with increasing puromycin concentration (0.5µg/ml – 5µg/ml) 
and cell viability was measured by flow cytometry based on the forward/sideward scatter and 
7-AAD dead cell exclusion staining. The minimal dose that killed >90% of uninfected cells was 
used to enrich for transduced cells. 
3.3.7 Flow cytometric analysis for fluorescent markers 
For analysis of lentivirally infected cells expressing fluorescent selection marker RFP 100µl of a 
dense cell culture (~1x105 cells) were harvested, washed once with 200µl PBS+2%FBS and 
resuspended in 100µl PBS+2%FBS. Cells were kept on ice until flow cytometric analysis. RFP 
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signal was analyzed at the LSRFortessa using the yellow/green (excitation: 561nm) laser. GFP 
signal was analyzed at the LSRII using the blue laser (excitation: 488nm). Dead cells were 
excluded by forward/sideward scatter. Duplet cells were excluded by area and height of the 
forward-scatter (FSC-A and FSC-H). 
3.3.8 RFP-growth competition assay 
The effect of shRNAs on viability or growth kinetics was tested by infection of BL cell lines at an 
infection rate of ~50% and subsequent flow cytometric analysis of RFP signal over 14 days. 
Cells were first measured at day 3 post-infection, when the RFP signal is fully expressed and 
the fraction of RFP-positive cells measured at later time points was normalized to the initial 
measurement.  
3.3.9 Intracellular staining for flow cytometric analysis 
Two alternative fixation methods were used: Methanol (MeOH) which leads to a loss of 
fluorescent markers and paraformaldehyde (PFA) which retains protein structures and 
fluorescent signal. ~2x106 cells were harvested and washed with PBS+2%FBS. For PFA fixation, 
cells are resuspended in 500µl 2% PFA and incubated for 30min at 4°C. After two washing 
steps, cells were resuspended in 1ml ice-cold 80% ethanol (EtOH) and incubated over night at  
-20°C. Before staining, cells were permeabilized in 100µl FIX&PERM Solution B, incubated for 
30min at RT in the dark and washed with PBS. For MeOH fixation, cells were resuspended in 
100µl PBS and 900µl ice-cold 100% MeOH were added drop-wise while shaking. Cells were 
incubated over night at -20°C. Before staining, cells were pelleted, resuspended in 1ml PBS and 
incubated for at least 30min at 4°C.  
p53 staining 
Fixated cells were resuspended in 100µl p53 staining solution (1:25 antibody dilution in 
PBS+2%FBS) using DO-1 antibody coupled to FITC (BD Pharmingen, BD Biosciences, San Jose, 
CA, USA), incubated for 1h at 4°C in the dark and washed and resuspended in PBS+2%FBS. 
Cell cycle analysis with 7-AAD 
Fixed cells were diluted in 50µl PBS with 100µg/ml RNase A (Qiagen, Hilden GER) and stained 
with 250µg/ml 7-AAD (BD Pharmingen). Before analysis cells are incubated for 30min at RT in 
the dark. 
3.3.10 Flow cytometric analysis of cell cycle phases by BrdU incorporation 
Analysis of cell cycle phases was performed using the BrdU Flow Kit from BD Pharmingen 
according to the manufacturer´s protocol. Cells were cultivated for 2-3h in the presence of 
1mM BrdU, harvested and fixated with PFA-based solutions provided in the kit. DNase I 
digestion opens up the DNA and makes it accessible to the APC-conjugated BrdU antibody. 
Total DNA content was stained by 7-AAD for distinction of Sub-G1, G1-phase, S-phase and 
G2/M-phase. Duplet cells were excluded by FSC-A to FSC-H. 
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3.3.11 Luminescent growth assay 
Cell viability and growth were measured by detection of ATP level using the CellTiter-Glo 
luminescent assay (Promega). 50µl of cells were seeded out in a white 384-well plate at a 
density of 1-3x105 cells/ml. Cells were incubated for 48h at 37°C. For detection of ATP-levels 
14µl CellTiter-Glo reagent was added to each well and incubated for 20min at RT in the dark. 
Luminescent signal was measured at the Tecan M-1000 multi-well plate reader. Optimal cell 
density was determined before by Katarzyna Tomska and Marina Lukas. 
3.3.12 Compound screen 
18 BL cell lines were analyzed by Katarzyna Tomska in a compound screen using 32 substances 
targeting key signaling pathways of lymphoma (see MD thesis, in preparation). In brief, cell 
density and incubation time were optimized to achieve logarithmic cell growth. Finally, all cell 
lines were incubated for 48h with 10 different substance concentrations diluted 1:3 starting 
from 30µM. As a negative control cells were treated with PBS or 0.1% DMSO corresponding to 
the final concentration of DMSO for substance dilutions. Cell viability was determined by ATP-
levels as described above (3.3.11). 
3.4 Molecular biology methods 
3.4.1 DNA extraction 
Genomic DNA was extracted from 2-5x106 cells using the DNeasy Blood&Tissue kit (Qiagen, 
Hilden, GER) according to the manufacturer´s instructions. In brief, cells were resuspended in 
lysis buffer, DNA was precipitated with 50% EtOH and bound to the membrane of a spin 
column. After washing, DNA was eluted from the membrane in pure H2O and quantified with 
the Qubit Fluorometer 2.0 using the dsDNA BR DNA kit (Invitrogen, Darmstadt, GER). 
3.4.2 Targeted resequencing with 454 technology 
For mutation analysis, target sequences in TP53 and MYD88 were amplified in two multiplex-
PCR reactions using primers that add a universal tag. The reaction mix and PCR program are 
listed below. PCR products were purified according to the Library Preparation Manual for GS 
Junior 454 sequencing (Roche, Basel, Switzerland) using 72µl AMPure beads (Invitrogen, 
Darmstadt, GER), 22.5µl PCR product, 22.5µl H2O. The mixture was incubated for 10min at RT 
to let PCR fragments bind to the oligo-nucleotide coated magnetic AMPure beads. The beads 
were pelleted on a magnet for 5min and washed twice with 70% EtOH. PCR products were 
eluted from air-dried beads in 10µl H2O. DNA was quantified using the PicoGreen assay 
(Invitrogen). Both multiplex-PCR reactions were pooled at equimolar ratios and in a second 
PCR reaction 454 sequencing adapters and sample-specific multiplex-identifiers were ligated to 
the PCR products. After AMPure bead purification using 45µl PCR product and 72µl AMPure 
beads, PCR products were resuspended in 10µl H2O, quantified in the PicoGreen assay and 
pooled equimolarly. The sequencing library was diluted to 5x105 molecules/µl and mixed with 
sequencing beads at a ratio of 0.5 molecules/bead. Emulsion PCR (emPCR) and 454 bi-
directional sequencing on the GS Junior benchtop sequencer were performed according to the 
manufacturer´s instructions “emPCR Amplification Method Manual – Lib-A” (March 2012) and 
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“Sequencing Method Manual” (March 2012) (Roche). Raw sequencing images were processed 
by the amplicon sequencing pipeline of the GSRunProcessor software (V2.5, Roche) and 
aligned to the reference sequence in the Amplicon Variant Analyzer software (V2.5, Roche). 
Variants were annotated according to the COSMIC data base (Sanger Institute). 
Mega-PCR 
PCR Step Temperature Time [min] 
1 95°C 2:00 
2 95°C 0:45 
3 57°C 0:45 
4 72°C 1:00 
5 GO TO STEP 2 30 TIMES 
6 72°C 5:00 
7 10°C FOREVER 
 
Titanium-PCR 
PCR Step Temperature Time [min] 
1 95°C 2:00 
2 95°C 0:45 
3 60°C 0:45 
4 72°C 1:00 
5 GO TO STEP 2 12 TIMES 
6 72°C 5:00 
7 10°C FOREVER 
 
3.4.3 Sanger sequencing 
Single amplicons were sequenced on the capillary sequencer ABI 3730xl (“Sanger” technology) 
at GATC Biotech (Constanz, GER). Target sequences were amplified in a PCR reaction according 
to the layout below, purified using the PCR purification kit (Qiagen, Hilden, GER) and quantified 
with the nanodrop spectrometer (Peqlab/VWR, Erlangen, GER).  
PCR Step Temperature Time [min] 
1 95°C 2:00 
2 95°C 0:45 
3 57°C 0:45 
4 72°C 1:00 
5 GO TO STEP 2 34 TIMES 
6 72°C 5:00 
7 10°C FOREVER 
 
 
 
 
Mega-PCR 
Reagent Volume [µl] 
H2O 21 
10x Buffer  5 
dNTPs 10mM each 1 
Taq Polymerase 0.5 
Primer mix 23 
gDNA (5ng/µl) 6 
TOTAL 50 
Titanium-PCR 
Reagent Volume [µl] 
H2O 41.5 
10x Buffer  5 
dNTPs 10mM each 1 
Taq Polymerase 0.5 
Titanium fwd+rev primer 
(10µM) 
1 
Mega-PCR (5ng/µl) 5 
TOTAL 50 
Reagent Volume [µl] 
H2O 40.5 
10x Buffer  5 
dNTPs 10mM each 1 
Taq Polymerase 0.5 
Primer fwd+rev 1 
gDNA (5ng/µl) 6 
TOTAL 50 
Materials and Methods 42  
3.4.4 Plasmid cloning 
shRNA expression plasmids 
shRNA sequences were taken from the DECIPHER human module 1 library (Cellecta Inc. 
Mountainview, CA, USA) and cloning was performed according to the protocol “Cloning of 
shRNA Templates into shRNA Expression Vector” (v3a, Cellecta). The sequences contain 
mismatches in the hairpin of up to 2 nucleotides to promote loading of the leading strand into 
the RISC complex. Forward and reverse single-stranded oligo-nucleotides were designed 
according to the schema below consisting of passenger strand, shRNA loop and leading strand. 
Sequences were flanked by a constant region and 5’-overhangs for restriction enzyme cloning 
into the pRSI12 vector backbone used for lentiviral expression.  
5’-ACCG-G-GCTGGTATTGTTGAGAATGAA-GTTAATATTCATAGC-TTCATTCTCAACGATGCCAGC-TTTT-3’ 
    3’- C-CGACCATAACAACTCTTACTT-CAATTATAAGTATCG-AAGTAAGAGTTGCTACGGTCG-AAAA-AAGC-5’  
Forward strand     
5’-Sticky end-Constant region-Passenger strand-shRNA loop-Leading strand-Constant region-3’ 
Reverse strand 
3’-Const. region-Passenger strand-shRNA loop-Leading strand-Const. region-Sticky end-5’ 
 
The empty pRSI12 vector was digested with BsbI restriction enzyme in 1x buffer G for 2h at 
37°C. After heat inactivation of the enzyme for 20min at 65°C the vector was purified from a 
0.5% preparative agarose gel using the QIAquick Gel Extraction kit (Qiagen, Hilden, GER). 
Phosphorylated shRNA oligo-nucleotides were ligated into the digested pRSI12 vector. The 
ligation mix was incubated for 30min on ice with 1µl ultra-competent XL10 Gold E.coli cells. 
Cells were heat-shocked at 42°C for 30sec, kept on ice for 2min and incubated with S.O.C 
medium for 1h at 37°C while shaking. Cells were plated on LB-agar containing 100µg/ml 
ampicillin and grown for 12h at 37°C. Insertion of shRNA sequence was tested in a PCR 
reaction (see template below) from single E.coli colonies. The same colonies were used to 
inoculate LB medium containing ampicillin to expanded cells for plasmid purification using 
either the GeneMatrix Plasmid MiniPrep kit (EURx, Gdansk, PL) or the EndoFree Plasmid Max 
kit (Qiagen). Plasmids were sent for sequencing at GATC Biotech using the pRSI9/pRSI12 
sequencing primer (CAAGGCTGTTAGAGAGATAATTGGAA). E.coli strains were preserved in glycerol 
solution and stored at -80°C. 
PCR Step Temperature Time in min. 
1 94°C 3:00 
2 94°C 0:20 
3 60°C 0:20 
4 72°C 0:20 
5 GO TO 2 30 TIMES 
6 72°C 2:00 
7 10°C FOREVER 
 
PCR Mix Vol. in µl 
H2O 16.4 
10x Buffer  2 
dNTPs 10mM each 0.4 
Taq Polymerase 0.4 
pRSI12-Colony-PCR- 
Primer mix (5 µM) 
0.8 
TOTAL 20 
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sgRNA expression plasmids 
sgRNA sequences were designed according to Shalem, Zhang et al., (Science, 2014). Oligo-
nucleotides contained 20bp target sequence (adjacent to “NGG” PAM sequence on genomic 
DNA) and 5’-overhangs for restriction enzyme cloning. The 5’-end should start with a G. 
forward 5’-CACCG-20bp target sequence     -3’ 
reverse 3’-    C-20bp target sequence-CAAA-5’ 
Vector backbone pLentiCRISPRv2 was digested with restriction enzyme BsmBI in FastDigest 
Buffer. Vector purification and sgRNA ligation was performed as described above for shRNAs. 
Sequencing was performed by GATC on a capillary sequencer using GTACAAAATACGTGACG 
sequencing primer. 
 
3.4.5 RNA extraction 
Total RNA was extracted from 2-5x106 cells using the RNeasy kit (Qiagen, Hilden, GER) 
according to the manufacturer´s protocol. The cells were washed in PBS, resuspended in lysis 
buffer and homogenisized through QiaShredder spin columns. RNA was precipitated from the 
lysate by 35% EtOH and RNA was bound to the membrane of a spin column. After washing, 
RNA was treated with DNase I for 15min at RT, washed and eluted in 30µl RNase-free H2O. 
RNA was quantified using the nanodrop spectrometer or the Qubit fluorometer.  
3.4.6 Reverse transcription quantitative PCR (RT-qPCR) 
Primers for qPCR were either designed (18-22bp, target region: ~100bp, exon-spanning) or 
taken from the RT primer bank (https://pga.mgh.harvard.edu/primerbank/). Primer efficiency 
was tested by RNA dilution series (maximal 30ng RNA, 4 times 1:10 dilutions). RT-qPCR was 
performed using the QuantiFast kit (Qiagen, Hilden, GER) according to the manufacturer´s 
protocol. 3-9ng of RNA in 3µl were added to 7µl of reaction mix containing forward and 
reverse primer (5µM each), enzymes and reagents for reverse transcription and qPCR 
amplification. qPCR was measured in white 96-well plates on the Cobas® z480 Analyzer (Roche, 
Basel, CH) using the program shown below. A primer melting curve was recorded to ensure 
specific target gene amplification. 
Step Cycles 
Analysis 
Mode 
Temp 
[°C] 
Acquisition 
Mode 
Time Ramp Rate 
Acquisition 
(per °C) 
Reverse 
Transcription 
1 None 50 None 10min 4.4 
 
Pre-
incubation 
1 None 95 None 5min 4.4 
 
Amplification 
40 Quantify 
95 None 10sec 4.4 
 
  60 Single 30sec 2.2 
 
Melting 
Curve 
  
1 
Melting 
Curve 
95 None 5sec 4.4 
 
65 None 1min 2.2 
 
97 Continuous 
 
0.11 5 
Cooling 1 None 40 None 30sec 2.2 
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3.4.7 RNA sequencing 
500 ng of total RNA were submitted to the Genomics and Proteomics Core Facility (GPCF) of 
the DKFZ. RNA quality was tested on a Bioanalyzer system (Agilent Technologies, Böblingen, 
GER) and quantified by Qubit using the RNA HS Assay Kit (Thermo Fisher Scientific, Waltham, 
USA). Single-read 50bp sequencing was performed on the HiSeq2000 sequencer (Illumina, San 
Diego, USA). Analysis of RNA sequencing data was performed by Zhiquin Huang and Marc 
Zapatka (DKFZ, Division of Molecular Genetics) as follows: RNA sequences were aligned to the 
hg19 human reference genome using the STAR alignment tool. HTSeq-count was used to 
calculate gene-level count and RPKM with annotation GENCODE version 19 GTF. 
3.4.8 Gene expression array 
For gene expression analysis 500ng total RNA were submitted to the DKFZ GPCF for analysis on 
the Illumina BeadChip® HumanHT-12-v4 containing >47,000 probes for 31,000 annotated 
human genes. Normalized relative expression values were provided by the GPCF. 
3.4.9 Immunoblot analysis 
For protein expression analysis cell lysates were prepared with RIPA buffer (150mM NaCl, 0.5% 
Na-Desoxycholate, 1% NP-40, 0.1% SDS, 50mM Tris pH 7.5; Merck/Millipore). Protein 
quantification was performed using the Pierce BCA Protein Assay kit (Thermo Fisher Scientific), 
a colorimetric assay. In brief, the cell lysate was incubated with BCA solution for 30min at 37°C. 
Protein reduces Cu2+ to Cu+ ions that react with bicinchoninic acid and form a purple substrate. 
Light absorption at 562nm is measured with the Tecan plate reader and the protein 
concentration was calculated based on a standard curve. For immunoblotting 40µg protein 
containing 1x Laemmli buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% 
bromphenol blue and 0.125 M Tris HCl, pH~6.8; Sigma-Aldrich) were separated by size on pre-
casted TGX gradient gels (4-15%) and transferred to a low-fluorescent PVDF membrane using 
the Trans-Blot Turbo Transfer system (Biorad). The membrane was incubated for at least 2h in 
TBS-T (137mM NaCl, 2.7mM KCl, 19mM Tris pH 7.4, 0.1% Tween 20) with 5% skim milk to 
reduce unspecific antibody binding. Primary antibodies were diluted in TBS-T with 5% BSA to 
increase specificity of binding and incubated over night at 4°C while shaking. Fluorochrome-
conjugated DyLight® (CST, Danvers, MA, USA) secondary antibody targeting mouse or rabbit 
proteins were used at a 1:15,000 dilution. Protein bands were detected using the Odyssey 
fluorescent scanner (Li-cor, Lincoln, NE, USA) and quantified using the ImageStudio software 
provided by Li-cor. 
3.5 RNAi screen 
3.5.1 shRNA library 
The DECIPHERTM Human Module 1 shRNA library (#DHPAC-M1-P) was obtained from Cellecta 
Inc. (Mountainview, CA, USA). It comprises 27,500 pooled shRNA sequences encoded on 
barcoded pRSI12 vector containing a puromycin resistance gene and red fluorescent protein 
(RFP) gene. The shRNAs target 5,045 genes in key signaling pathways. The manufacturer 
provided sequencing results for the plasmid library. 
Materials and Methods 45  
3.5.2 Lentiviral packaging of shRNA library 
Lentiviral packaging of the shRNA library was performed according to the Cellecta protocol 
“Pooled Lentiviral shRNA Libraries” (v5e, 9/6/13). HEK293T/17 cells were plated on 10x 15cm 
cell culture dishes at 8x104 cells/cm2 and grown for 24h to reach ~80% confluency. The 
transfection mix consisting of 300µg packaging plasmid mix (psMD2.G:psPAX2 , 1:2), 60µg of 
plasmid library DNA, 600µl PLUS reagent and 12ml Opti-MEM was incubated at room 
temperature for 15min. 900µl lipofectamine in 12ml Opti-MEM were added to the transfection 
mix and incubated at room temperature for 15min. The final mixture was distributed equally 
among the plates. After 24h of incubation the supernatant was replaced with fresh medium 
containing 1U/ml DNase I and 4nM MgCl2 and cells were grown for 24h. The transfection 
efficiency was estimated based on RFP-expression in fluorescent microscopy. The supernatant 
from all plates was combined and filtered through a 0.45µm filter and stored in aliquots at        
-80°C. 
3.5.3 Titration of lentiviral supernatant  
The lentiviral supernatant of the packaged pRSI12 shRNA library was titrated on BL cell lines 
selected for the screen to determine the amount of virus needed for ~50% (MOI=0.7) infection 
rates. Cells were seeded out at 5x105 cells/ml, incubated for 3 days in the presence of 
increasing volumes of lentiviral supernatant and RFP was measured in flow cytometry using 
the yellow-green laser (excitation at 561nm) of the LSR FortessaTM (BD Biosciences, San Jose, 
CA, USA). 
3.5.4 RNAi screen in 8 BL cell lines 
Cell lines were transduced with the shRNA library at ~50% infection rate. Every shRNA was 
infected 80 times (5.4x106 cells) in three replicates. Cells were cultured for 2 days and ⅓ of the 
culture was harvested as a baseline. The remaining culture was treated with puromycin for 48h 
at the minimal lethal dose. After renewal of the medium cells were grown in two separate 
replicates for 10 days in logarithmic growth phase (cell density 4x105 cells/ml - 1.5x106 
cells/ml). During sampling >1,000-fold representation of shRNAs was maintained. Harvested 
cells were washed with PBS, snap-frozen in liquid nitrogen and stored at -80°C. For extraction 
of genomic DNA, cells were resuspended in P1 buffer (Qiagen, Hilden, GER) containing 
100µg/ml RNase A and 0.5% SDS and incubated for 5min at RT. Genomic DNA was sheared into 
10-100kbp fragments by sonication (6 cycles, full power, 10 sec pulse). DNA was extracted with 
phenol/chloroform (pH 8.0), precipitated with isopropanol in the presence of 3M sodium 
acetate and washed with 70% EtOH. The air-dried DNA pellet was eluted in water and 
quantified using Qubit fluorometer (Invitrogen, Darmstadt, GER). shRNA vector barcodes were 
amplified from 200µg genomic DNA (or the maximum available amount) in 4x 50µl PCR 
reactions using FwdHTS and RevHTS1 primer. 
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Reagent Volume [µl]  Temperature [°C] Time [sec] 
H2O 15.5 1 94 180 
10x Titanium Taq buffer 5 2 94 30 
Genomic DNA (1µg/µl) 25 3 65 10 
FwdHTS (10µM) 1.5 4 72 20 
RevHTS1 (10µM) 1.5  Go to 2 16 cycles 
dNTP mix (10mM each) 1 5 68 120 
Titanium Taq 0.5 6 10 store 
  
In a second, nested PCR target sequences were amplified with optimized number of cycles (to 
avoid over-cycling) and sample-specific multiplex identifier sequences, that allow pooling of 
multiple samples on one sequencing lane, were added by the reverse RevGex primer.  
Reagent Volume [µl]  Temperature [°C] Time [sec] 
H2O 37.5 1 94 180 
10x Titanium Taq buffer 5 2 94 30 
1
st
 round PCR product 1 3 65 10 
FwdGex (10µM) 2.5 4 72 20 
RevGex (10µM) 2.5  Go to 2 12-18 cycles 
dNTP mix (10mM each) 1 5 68 120 
Titanium Taq 0.5 6 10 store 
PCR products of 255bp were analyzed on a 2.5% agarose gel, purified using the QIA quick PCR 
purification kit (Qiagen) and quantified with nanodrop (Peqlab, Erlangen, GER).  
3.5.5 Sequencing of shRNA vector barcodes 
Six samples each were pooled at equimolar ratios and submitted at 10nM to the DKFZ GPCF for 
50bp single-end sequencing on one lane of the Illumina HiSeq2000 (Table 1). The GexSeqS 
sequencing primer binds directly in front of the 18nt shRNA barcode and is added first to the 
sequencing reaction (Figure 9).  
 
Figure 9: Primers for sequencing of the shRNA library 
Part of the pRSI12 vector sequence with indicated shRNA barcode sequence, amplification (1st 
round PCR: blue; 2nd round PCR: pink) and sequencing (green) primers. 
In order to avoid that the sequencer loses the focus “random” sequences from PhiX virus were 
added to the library to dilute the signal of the vector backbone (60% library : 40% PhiX). The 
indexing sequences were read in a second sequencing reaction replacing the Gex2M 
(sequencing primer for uniplex samples) with the GexSeqIND. 
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Table 1: Indexed shRNA screening samples 
Cell line Time point # of cells DNA [µg] Lane Index Coverage 
BJAB Day 2 
Day 14_rep1 
Day 14_rep2 
3.7x10
7
 
1.5x10
8
 
1.5x10
8
 
122 
970 
714 
1 ATGC 
GACT 
TCAG 
27,050,695 
16,556,211 
7,184,670 
BL60 Day 2 
Day 14_rep1 
Day 14_rep2 
3.0x10
7
 
2.5x10
8
 
2.5x10
8
 
62 
1650 
1920 
1 CGTA 
AGCG 
GATG 
34,250,997 
12,908,933 
14,104,821 
Raji Day 2 
Day 14_rep1 
Day 14_rep2 
2.0x10
7
 
2.3x10
8
 
2.3x10
8
 
116 
1420 
1580 
2 ATGC 
GACT 
TCAG 
18,474,328 
20,090,539 
30,158,731 
Ramos Day 2 
Day 14_rep1 
Day 14_rep2 
4.3x10
7
 
3.2x10
8
 
3.2x10
8
 
123 
1080 
1120 
2 CGTA 
AGCG 
GATG 
20,471,635 
13,286,388 
17,430,929 
BL-2 Day 2 
Day 14_rep1 
Day 14_rep2 
3.1x10
7
 
3.2x10
8
 
3.2x10
8
 
50 
915 
1479 
3 ATGC 
GACT 
TCAG 
23,851,748 
8,080,939 
22,043,318 
LY47 Day 2 
Day 14_rep1 
Day 14_rep2 
1.1x10
7
 
2.3x10
8
 
2.3x10
8
 
30 
415 
418 
3 CGTA 
AGCG 
GATG 
25,713,683 
7,416,915 
5,452,051 
Salina Day 2 
Day 14_rep1 
Day 14_rep2 
1.5x10
7
 
4.4x10
8
 
4.4x10
8
 
52 
1275 
1856 
4 ATGC 
GACT 
TCAG 
25,011,187 
10,023,296 
23,214,458 
Seraphine Day 2 
Day 14_rep1 
Day 14_rep2 
1.1x10
7
 
1.7x10
8
 
1.7x10
8
 
37 
668 
538 
4 CGTA 
AGCG 
GATG 
33,684,767 
13,147,547 
20,649,830 
 
 
3.5.6 RNAi data analysis 
Barcode identification. Multiplexed samples were deconvoluted by the DKFZ GPCF based on 
the index sequence. Raw sequencing reads were trimmed to 20bp reads using the python 
script “Gzim_Trim”. Barcode sequences were identified using the DECIPHER bar code 
deconvoluter software (version 2010-10-05) and the library reference file (BLIB). Settings of 
the software were changed to “Allow 1 error” and “Correct N symbol”. The 2bp module 
identifier (AT for module 1) was not needed, as we did not pool different modules. The 
software created a tab delimited file containing the counts for all identified barcodes.  
Normalization. To account for differences in the coverage of the samples, relative shRNA 
counts were calculated by dividing of every raw read count with the mean read count of the 
same sample. As replicates on day 14 were highly correlated, the mean of both replicates was 
calculated for every shRNA. Relative shRNA counts on day 14 were divided by relative counts 
on day 2 to calculate fold-changes (FC) for each cell line. After logarithmic transformation with 
the basis 2 all values were normalized across cell lines by peak median absolute deviation 
(PMAD) using the GenePattern module “NormLines” provided by the Broad Institute. For each 
cell line, every shRNA value is divided by the modeled peak value and divided by the median 
absolute deviation. 
Class comparison. Analysis of differentially expressed shRNAs was performed using GENE-E 
software with RIGER extension provided by the Broad Institute. The table of PMAD-normalized 
logarithmic fold-changes was saved as a .gct format (tab delimited file containing two header 
rows: “#1.2” in A1, “# of data columns” in B1, “# of data rows” in B2) and opened in GENE-E. 
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TP53 status of cell lines was added using the .cls class definition file and scores for differential 
shRNA representation were calculated using RIGER algorithm. shRNAs were scored and ranked 
for their ability to distinguish between two classes using „Weight of evidence“ (WoE) statistics. 
WoE scores for shRNAs targeting the same gene were combined into gene scores and ranks 
using Kolmogorov-Smirnov (KS) statistics. 
edgeR. Gene depletion scores were calculated using the edgeR package and Fisher z-
transformation as described previously131,132. In brief, raw sequencing reads for all samples 
were combined. The pipeline requires replicate measurements that were not available for day 
2 samples. However, as shRNA representation on day 2 was highly correlated within all cell 
lines, an artificial replicate for each cell line was calculated based on the mean shRNA count for 
the remaining cell lines. shRNAs were sorted by abundance on day 2 (mean over all cell lines) 
and the top 5% were removed to avoid strong outliers when the fold-changes were calculated. 
Control shRNAs that were represented in triplicates were removed and missing values were 
replaced by 10. For every cell line, the edgeR package was used to normalize every sample for 
library size, calculate the dispersion of the data and fit a negative binomial model. P-values for 
shRNA distribution were calculated by carrying out a likelihood ratio test and adjusted for 
multiplicity of testing by FDR method. P-values for shRNAs targeting the same gene were 
combined into gene depletion scores using weighted z-transformation (wZ-scores). 
Removal of overlapping shRNAs. A script for identification of shRNAs with overlapping target 
region was generated by Agnes Hotz-Wagenblatt (DKFZ) shRNA sequences were mapped 
against the human transcriptome using Tophat2 algorithm (Ensembl v75). 
To identify candidate genes we applied the following criteria: 
(1) Genes with significantly lower shRNA counts in p53wt by KS score (p-value < 0.05): Using 
the KS gene scores as described above we identified 324 genes that had significantly lower 
shRNA counts in p53wt cell lines.  
(2) Genes with significantly lower shRNA counts in p53wt by 2nd best shRNA (p-value < 0.05): 
Following a similar approach as for the calculation of KS gene scores, all shRNAs were ranked 
for their differential representation. Instead of calculating a combined score over all shRNAs 
genes were ranked by the second strongest shRNA that discriminates between the groups. This 
step selects genes with at least two strong differential shRNAs. 150 genes showed significantly 
lower shRNA counts using both ranking methods from step (1) and step (2). 
(3) Genes essential in p53wt (median wZ-score < -0.5): We further classified genes with lower 
shRNA counts in p53wt by their wZ-score into genes depleted in p53wt or genes enriched in 
p53mut. For example, the pro-apoptotic gene BAD was on rank 21 by KS score, but was not 
essential in p53wt by wZ-score (median wZ = -0.15). Instead, shRNAs targeting BAD were 
enriched in p53mut cell lines (median wZ = 1.37). In comparison, the gene MDM4 which was 
the highest ranking gene by KS score was essential in p53wt (median wZ = -1.79), but not in 
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p53mut (median wZ = 0.29). To select for essential genes in p53wt, we set the cut-off to a 
median wZ-score of -0.5 and identified 59 genes fulfilling this criteria.  
(4) Filtering for expressed genes: We further filtered out genes that were not found to be 
expressed in published RNA sequencing data of three BL cell lines, including the Raji cell line133. 
46 out of 59 genes (78%) were expressed indicating low noise in the data. 
(5) Removal of shRNAs with overlapping target region: Some of the shRNAs have overlapping 
target regions. These shRNAs may exert similar effects resulting into biased gene scores. We 
mapped all shRNAs against the genome and calculated the number of base pairs that overlap 
within the same gene (see 3.5.6). Four genes were removed from the list of candidates 
because the gene score was influenced by overlapping shRNAs.  
(6) Significant difference of gene depletion score (p<0.05): We further prioritized 12 genes that 
show a significant difference in their wZ-score meaning that they are significantly stronger 
depleted across all four p53wt cell lines. 
  
(7) Common essential genes (median wZ in p53mut<-0.5): Four genes that showed a median 
wZ-score below -0.5 in the p53mut cell lines were categorized as common essential genes. 
# of genes in p53wt Filtering criteria # of genes in p53mut 
324 Significant by KS score 269 
150 Significant by 2nd best shRNA 132 
59 Depleted in this class 52 
46 Expressed by RNA sequencing 46 
42 After removal of biased shRNAs 44 
12 Significant difference in gene wZ-score 19 
4 Generally toxic 16 
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4 Results 
For the systematic identification of genes essential in Burkitt lymphomagenesis, we analyzed 
associations of recurrent genetic alterations in primary BL samples from the MMML 
consortium and integrated our findings with a functional genomics screen for p53-specific 
vulnerabilities in BL cell lines. 
 
4.1 Pattern of recurrent mutations and CNVs in BL  
To improve our understanding of failsafe mechanisms in MYC-driven lymphoma we 
systematically analyzed the pattern of recurrent genomic alterations in 59 primary BL samples 
(MMML consortium).  
The pattern of MYC and TP53 mutations in BL patients is shown in Figure 10. The MYC gene 
was mutated in 59% of BL patients (n=37) and carried multiple mutations as a result of somatic 
hypermutation (average number of mutations in conserved regions: 1.7). MYC box I mutations 
increase oncogenic potential by impaired induction of pro-apoptotic Bim, presumably as an 
alternative to p53 inactivation65. The conserved MYC box I residues P57 and T58 were affected 
in 17% of patients (n=11). TP53 mutations were frequently observed (n=27, 43%) and mainly 
comprised missense mutations in the DNA binding domain that lead to a loss of its tumor 
suppressor function. Notably, MYC box I mutations occurred independent of TP53 mutations. 
 
Figure 10: TP53 and MYC box I mutations in Burkitt lymphoma patients. 
Incidence and co-occurrence of TP53 and MYC box I mutation in 59 BL patients (MMML 
consortium). Each column represents one patient and the mutation status is indicated. 
 
To study their clinical impact we analyzed correlations between TP53 mutation and clinical 
parameters. Patients carrying TP53 mutations displayed with higher clinical stage (p=0.017) 
and more extranodal involvement (p=0.016) (Figure 11A). However, we did not observe a 
significant difference in overall survival of TP53 mutant and wild type patients (Figure 11B). 
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Figure 11: Clinical impact of TP53 mutations in Burkitt lymphoma 
(A) Clinical parameters were correlated to the TP53 mutation status. The table shows 
significantly correlated parameters (p<0.05). E=extranodal; N= nodal; NE=nodal and extranodel 
(B) Overall survival of 34 p53wt and 29 p53mut BL patients. 
 
To find alternative mechanisms that may contribute to failsafe checkpoint inactivation in BL, 
we compared recurrent copy number variations (CNVs) in 38 p53 wild-type (p53wt) and 29 p53 
mutant (p53mut) BL samples (Figure 12A). p53mut samples showed a trend towards a more 
complex karyotype compared to p53wt BL (p=0.107). p53 mutations co-occurred with deletion 
of the p53 locus chr17p13 (5/6 patients, p=0.075). In addition, we observed an unexpected 
overrepresentation of chromosome 1q32 gain in p53wt BL (p53mut=24%, p53wt=42%, 
p=0.055). The gain on chr1q was the second most common CNV besides of the MYC 
translocation, confirming previous findings33,48. An association of chr1q gain with p53 status in 
BL has not been described before and suggests a novel oncogenic mechanism exclusive to p53 
mutation. 
A detailed analysis of the architecture of chr1q CNV in p53wt BL showed partial chromosomal 
gains in 37%, while in 5% the complete chr1q arm was affected. Minimally gained regions 
(MGR) comprised 1q21.1-q23.3, 1q24-q25 and 1q32.1 (Figure 12B left). Chr1q amplifications 
affect large regions and the pathogenic role of single deregulated genes remains elusive. We 
used RNA expression analysis to query potential genes involved in chr1q gain. Figure 12C lists 
cancer consensus genes that were located within MGR and found to be upregulated in patients 
with chr1q gain.The association of chr1q gain with p53 mutation status was specific for BL and 
not observed in diffuse large B-cell lymphoma (DLBCL), where amplifications on chr1q were 
equally distributed in p53wt and p53mut patients (p53mut=22%, p53wt=23%) and mostly 
affected the whole arm of the chromosome rather than partial trisomies (B, right). 
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Figure 12: Differential copy number variations in p53wt Burkitt lymphoma. 
(A) Copy number variations (CNVs) determined by comparative genome hybridization array 
(CGHa) in 29 p53mut and 38 p53wt BL. Gains (positive values) are shown in green and losses 
(negative values) are shown in red. (B) Fraction of gains on chromosome 1q at a higher 
resolution in p53mut (red) and p53wt (green) patients. left: BL; right: DLBCL. (C) List of cancer 
consensus genes located within minimally gained regions of p53wt BL that show a gene-dosage 
effect. 
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4.2 RNAi screen identifies p53-specific vulnerabilities 
4.2.1 Selection of cell line models  
To study specific dependences in BL with wild-type p53 we selected cell line models 
representing p53wt and p53mut patients. The majority of BL cell lines harbors p53 mutations 
(80%). We obtained 6 p53wt cell lines and selected 8 commonly used p53mut cell lines for 
further characterization. The mutation status was confirmed by targeted resequencing of 
exons 4-10. Four out of six p53wt cell lines could be efficiently infected with lentiviral vectors 
and were chosen for the screen (BL-2, LY47, Salina, Seraphine). According to the published 
cytogenetic profile all of them harbor a gain on chr1q47. Seraphine carries a duplication of the 
whole chr1q-arm. BL-2 and Salina show a partial duplication of chr1q21.2-q31.3 and LY47 of 
the distal chr1q43-q44 region. All p53mut cell lines could be infected with lentiviral vectors, 
therefore we chose four cell lines that differ in their p53 mutation and have normal chr1q copy 
number (BJAB, BL60, Raji, Ramos), reflecting the karyotype of BL patients. All cell line 
characteristics are listed in Table 2.  
Table 2: Genetic characteristics of cell lines used in the RNAi screen 
WT = wild-type; MUT = mutant; EBV = Epstein-Barr-Virus; +(III) = EBV latency III phase; +(Wp) = 
EBV Wp-restricted latency III 
Name TP53  
status 
MYC box I 
status 
Chr1q 
gain 
EBV  
status 
t(MYC) 
BJAB p.H193R WT Normal - t(8;14) 
BL60 p.R248W WT Normal + (III) FISH+ 
Raji p.R213Q; 
p.Y234H 
MUT (boxI) Normal + (III) t(8;14) 
Ramos p.I254D WT Normal - t(8;14) 
BL-2 WT MUT (boxI) +1q21.1q31.3 - t(8;22) 
LY47 WT WT +1q43q44 + (III) t(8;22) 
Salina WT WT +1q21.2q31.3 + (Wp) t(8;14) 
Seraphine WT WT +1q21.1qter + (III) t(8;14) 
 
To further characterize the cell lines, we investigated additional features which could impact 
the screen results. The MYC translocation characteristic for Burkitt lymphoma was reported in 
seven cell lines and in BL60 we confirmed its presence by FISH analysis. MYC box I mutations 
were present in one cell line of each group. Many BL cell lines are naturally infected and 
transformed by EBV. This has to be taken into consideration as viral proteins expressed in the 
latency III phase of the virus (like EBNA-3C and LMP-2A) deactivate the p53 pathway and 
promote survival134,135. In the group of p53wt cell lines BL-2 was EBV-negative while the 
remaining three cell lines were EBV-positive and expressed latency III genes. LY47 and 
Seraphine expressed genes from the Cp-promoter leading to a single transcript encoding all 
genes, while Salina expressed a shorter transcript from the alternative Wp-promoter 
containing genes of the restricted latency III phase. Two of the p53mut cell lines, BL60 and Raji, 
were positive for EBV and expressed full latency III genes, whereas Ramos and BJAB were EBV-
negative. 
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In summary, we ensured an equal distribution of MYC box I mutations and EBV infection 
between p53wt and p53mut cell lines to avoid biases in group comparison analysis. 
 
4.2.2 shRNA screening layout 
To identify genes that are essential in p53wt, but not in p53mut BL cell lines, we performed a 
loss-of-function RNAi screen in the selected cell lines (Figure 13). We used a pooled shRNA 
library for systematic downregulation of 5,045 genes in key signaling pathways with five to six 
independent silencing trigger per gene. After lentiviral delivery, the shRNAs integrate into the 
genome, are stably expressed and target a complementary mRNA for degradation. The shRNA 
representation was determined on day 2 and on day 14 after transduction by high-throughput 
sequencing of sequence-optimized vector barcodes. Silencing trigger that target essential 
genes were lost over time. While common essential genes showed shRNA depletion in all cell 
lines p53-specific essential genes were only lost within the group of p53wt or p53mut cell 
lines, respectively.  
 
Figure 13: Scheme of the shRNA screen for identification of p53-specific vulnerabilities.  
4 p53wt and 4 p53mut BL cell lines were transduced in triplicates with a pooled shRNA library 
using lentiviral transfer. On day 2 one replicate was harvested as baseline control. After 
enrichment of infected cells with puromycin the cell pool was divided into half for technical 
replicates. Both replicates were harvested on day 14 post-infection. shRNA representation on 
day 2 and day 14 was determined by high-throughput sequencing of vector barcodes. shRNAs 
targeting essential genes (blue) were depleted from the pool in both cell line groups, while 
cells infected with shRNAs against non-essential genes (grey) were propagating normally. 
shRNAs that are depleted only from the group of p53mut (red) or p53wt (green) cell lines 
identify p53-specific essential genes. 
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4.2.3 Establishment of the RNAi screen 
The shRNA plasmid library was packaged into lentiviral particles using HEK293T/17 cells and 
the efficiency of packaging was monitored by RFP-expression in fluorescent microscopy (Figure 
14A). The lentiviral supernatant was titrated on the target cells to determine the amount 
needed to infect ~50% of cells. Using low virus titers in the screen reduced the number of cells 
infected with multiple shRNAs. Infection rates were measured by flow cytometric analysis of 
RFP signal on day 3 post-infection (Figure 14B). First, 20µl, 50µl and 100µl of the lentiviral 
supernatant were added to BL-2 and Raji (Figure 14C, left). Optimal infection rate was 
obtained for lower volumes of added viral supernatant and similar volumes were used for 
titration on the six remaining cell lines (Figure 14C, right). For all cell lines, the rate of infected 
cells increased linearly with the volume of added virus, which allowed determining the optimal 
condition for each cell line. To test cytotoxic effects of the shRNA library the ratio of 
RFP+/shRNA+ and RFP-/shRNA- cells was monitored over time. RFP was stably expressed in 
cells infected with a non-targeting shRNA (shNT), while RFP-signal was depleted in cells 
infected with the shRNA library (Figure 14D). This suggests that shRNAs targeting essential 
genes were depleted during this time course and we chose 14 days of incubation for the 
screen as this resulted into a drop of RFP-signal of at least 50%. We did not observe an 
increase in apoptosis by Annexin-V staining (data not shown). Apoptosis is a fast process and 
as the expression of shRNAs was not synchronized in the cells we cannot exclude that our 
method was not sensitive enough to detect an increase in apoptotic cells. 
Figure 14: Establishment of the RNAi screen 
(A) HEK293T/17 cells in light microscopy (left) and fluorescent microscopy (yellow/green filter; 
right) during lentiviral packaging of the shRNA library; scale: 50µm. (B) Exemplary analysis of 
RFP signal in flow cytometry (left: uninfected; right: infected). Dead cells were excluded by 
FSC/SSC. (C) Titration of lentiviral supernatant on BL cell lines. RFP signal was measured on day 
3 post transduction. (D) Time course for RFP-signal depletion in cell lines infected with a non-
targeting shRNA (shNT, black) or the shRNA library (orange).  
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4.2.4 RNAi screen 
The RNAi screen was performed according to the layout described in section 4.2.2. The 
infection rates were determined in a small sub-culture that was not treated with puromycin. 
For all cell lines we achieved the desired infection rate between 40% and 60% (Figure 15A, 
left). Starting from day 5 post-infection, the RFP-signal dropped steadily in all cell lines as 
observed previously (Figure 15A, right). Puromycin treatment efficiently enriched infected cells 
to 88-99% (Figure 15A, right). Cell lines with >90% enriched cells stably expressed RFP over 14 
days. Three cell lines with <90% enriched cells (LY47, Seraphine and Raji) showed a drop of 
RFP-signal to ~70% of the total population. Genomic DNA was extracted from cells on day 2 
and day 14 (2 replicates) after infection and unique barcode sequences corresponding to 
shRNA vectors were amplified in a two-step PCR reaction. We pooled six samples for 
sequencing on one lane of the HiSeq2000 (Illumina, San Diego, CA, USA) and controlled the 
quality of pooled PCR amplicons on a Bioanalyzer (Agilent Technologies, Böblingen, GER) 
(Figure 15B). The analysis showed a single PCR product of the expected size.  
Figure 15: Infection rates and library preparation  
(A) RFP-signal was determined over 14 days in a subculture without puromycin and in the main 
bulk of the culture treated with puromycin for 48h (red area) to enrich for infected cells. The 
infection rate was determined by the fraction of RFP-positive cells on day 3 post-infection 
without puromycin (red line). (B) Electrophoresis of amplified and indexed barcode sequences 
on the Bioanalyzer (Agilent Technologies, Böblingen, GER). The PCR products have a size of 
255bp. The lower and the upper peak are DNA markers used for calibration. 
 
4.2.5 Visualization of shRNA screening results 
To assess the quality of obtained screen results we first compared the representation of 
shRNAs within the plasmid library (as provided by the manufacturer) with the shRNA 
representation on day 2 post-transduction in all eight cell lines. All shRNAs were detected and 
highly correlated with the plasmid library (R²>0.8) (Figure 16A). The correlation between cell 
lines was even stronger (R²>0.9), suggesting that lentiviral packaging and batch effects of the 
plasmid library have a greater impact than lentiviral infection (Figure 16B). The distribution of 
shRNA counts resembled a Gaussian distribution (Figure 16C) confirming that no major toxicity 
effects were visible on day 2. 
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Figure 16: shRNA library representation on day 2. 
(A) Raw shRNA counts were normalized for different library abundance. After logarithmic 
transformation relative shRNA counts on day 2 were plotted against the library representation 
and the correlation was calculated. (B) Correlation matrix between library and day 2 shRNA 
counts. The color scale displays R2-values. (C) Density plot displaying the distribution of shRNA 
counts. 
 
Replicate measurements on day 14 were highly correlated within the same cell line (R2>0.9), 
but differed across cell lines (median R2=0.65) indicating cell line specific shRNA depletion 
(Figure 17B). Using the average over both replicates, we analyzed changes in shRNA 
representation compared to day 2 (Figure 17A, C). In all cell lines shRNAs were depleted on day 
14, but no enrichment could be observed. The strength of shRNA depletion was not influenced 
by the number of cell divisions, as cytotoxic effects were strong in LY47, the slowest growing 
cell line, but weak in Ramos, the fastest growing cell line. 
B 
A 
C 
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Figure 17: shRNA library representation on day 14. 
(A) As described for the day 2 time point, raw shRNA counts were normalized for differences in 
library abundance. In addition, the mean over both replicates was calculated. After logarithmic 
transformation mean relative shRNA counts on day 14 were plotted against relative counts on 
day 2 of the same cell line and the correlation was calculated. (B) Correlation matrix for day 2 
and day 14 replicate (R1 and R2) shRNA counts. (C) Density plot displaying the distribution of 
shRNA counts on day 14 (mean of both replicates). 
 
4.2.6 Common essential and non-essential genes 
To identify essential genes, we established an analysis pipeline based on published 
algorithms131,132. A detailed description can be found in the methods section 3.5.6. In brief, 
using the edgeR Bioconductor package we fitted a generalized linear model that tests if 
shRNAs were preferentially depleted or enriched. The resulting p-values were adjusted for 
multiple testing. We then combined p-values of shRNAs targeting the same gene by weighted 
z-transformation into gene depletion scores (wZ-scores). Figure 18A shows an exemplary 
shRNA distribution for the essential ribosomal protein RPL30 and the non-essential gene 
APOA4. While shRNAs against APOA4 were randomly distributed across the whole data set, 
B C 
A
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shRNAs targeting RPL30 were significantly depleted. After collapsing of shRNA values into gene 
depletion scores, RPL30 was specifically identified as one of the top-ranking essential genes 
(Figure 18B).  
Figure 18: Identification of essential and non-essential genes from the RNAi screen. 
Exemplary graphs depicting the data analysis approach using the edgeR package for 
comparison of count data. (A) Likelihood for shRNAs of being randomly distributed across the 
whole data set. The grey curve marks all data points. Distribution of shRNAs targeting the 
essential RPL30 gene (red), compared to the non-essential APOA4 gene (blue) are indicated. 
(B) Based on the shRNA distribution gene depletion scores were calculated by weighted z-
transformation. Every data point represents one gene and genes with significantly depleted 
shRNAs were located within the tails of the curve.  
 
To evaluate the performance of our screen, we first analyzed the most essential genes 
common to all cell lines based on the median depletion score. Within the 100 top-scoring 
genes we observed a strong enrichment for ribosomal, proteasomal and spliceosomal genes 
(Figure 19A). Furthermore, we probed the depletion scores against a published gene set of 
general essential and non-essential genes115. Our screen covered 222 genes that were 
classified as “non-essential” (NE) or “constitutive core essential” (CCE) based on the overlay of 
multiple independent RNAi screens in cell lines across cancer entities. Our data showed a high 
overlap: While genes classified as NE had unchanged shRNA counts, genes classified as CCE 
showed strong negative depletion scores (Figure 19B). Genes from the three enriched KEGG 
signaling pathways were found in the group of CCE, but not in NE genes (Figure 19C). Within 
the 100 most essential genes 35 genes were classified as “CCE” while 1-2 would be expected 
by chance. Notably, cell lines did not cluster by TP53 mutation status. Therefore, the strength 
of shRNA depletion for common viability genes was not influenced by the presence of mutant 
or wild-type p53. This data suggests that the screen can reliably identify genes essential for cell 
viability and growth.  
 
 
shRNA distribution:  
p-value for fold-changes 
Gene depletion score:  
weighted z-transformation 
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Figure 19: General essential and non-essential genes 
(A) For every gene the median depletion score over all cell lines was calculated. The 100 top 
ranking genes were probed against KEGG gene sets using the GSEA tool from the Broad 
Institute. (B) Distribution of gene depletion scores for all genes (black) and genes classified as 
“constitutive core essential” (CCE, red) or “non-essential” (NE, blue)115. (C) Clustering of gene 
depletion scores by Euclidian distance for 220 genes classified as CCE or NE (top). The lower 
heatmap shows a magnification of the two most distinct gene clusters. 
 
4.2.7 Genotype-specific essential genes 
To identify genes essential in a subset of cell lines with defined genetic background, we 
adapted bioinformatics tools provided by the Broad Institute to rank genes based on their 
differential shRNA representation. The tools were developed and optimized to analyze loss-of-
function screens in hundreds of human cancer cell lines as part of the “Achilles” project that is 
discussed in further detail in section 4.3.8113. The layout of the analysis pipeline is depicted in 
Figure 20A and further details can be found in the method section 3.5.6. In brief, for every cell 
line we calculated fold-changes of shRNA counts between day 14 and day 2. To account for 
differences in data dispersion we normalized the shRNA values for each cell line using peak 
median absolute deviation (PMAD) (Figure 20B). We then examined the position of every 
shRNA across the whole data set in p53wt versus p53mut cell lines and compared if shRNA 
A B 
C 
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counts were significantly lower/higher in one of the groups. The comparison was performed 
using “weight-of-evidence” statistics that ranks shRNAs according to their strength to 
differentiate between two groups. Finally, we collapsed shRNA scores into gene scores using 
KS statistic to test if shRNAs targeting the same gene are biased towards lower/higher 
representation in one of the groups. This group comparison can be performed in both 
directions: Genes on top of the ranking list show consistently lower shRNA counts in group A, 
while genes on the other side of the ranking show lower shRNA counts in group B.  
 
Figure 20: Identification of genotype-specific essential genes 
(A) Schematic overview of the analysis pipeline for identification of genotype-specific essential 
genes. PMAD = peak median absolute deviation, KS = Kolmogorov-Smirnov statistic (B) 
Normalization of shRNA fold-changes between cell lines using PMAD. (C) Ranked shRNAs 
scored by differential representation in BL-2 (MYD88 mutant) and 7 MYD88 wild-type BL cell 
lines. (D) Genes ranked based on the power of the shRNAs to discriminate between MYD88 
mutant and wild-type BL cell lines. The essential and non-essential genes shown here are the 
genes from Figure 19C. 
 
We tested the approach on a previously described genetic dependence. Using a self-
established platform for targeted resequencing of genes that are recurrently mutated in 
lymphoma we identified the MYD88 mutation S219C in the BL-2 cell line. A previous study 
reported a strong dependence of MYD88-mutant ABC DLBLC on MYD88 itself or its 
downstream mediator IRAK1136. This was shown for the characteristic hotspot mutation L265P 
which occurs most frequently in ABC DLBCL, as well as for the less frequent S219C mutation. In 
our RNAi screen, shRNAs targeting MYD88 or IRAK1 showed significantly lower shRNA counts 
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in BL-2 (Figure 20C). Importantly, using our class comparison approach we identified IRAK1 on 
rank 4 and MYD88 on rank 5 of genes specifically essential in BL-2 (Figure 20D). This suggests 
that the pipeline can be used as an unbiased statistical approach to identify novel gene 
dependences.  
 
4.2.8 p53-specific essential genes 
We applied the same analysis pipeline as described for MYD88 to identify p53-specific 
essential genes. shRNAs were ranked according to their differential representation in 4 p53wt 
versus 4 p53mut cell lines. As shown in Figure 21A shRNAs targeting general essential (e.g. RPL30) 
or non-essential (e.g. APOA4) genes were equally represented in both groups, while individual genes 
(e.g. MDM4, CDKN3) showed consistently lower shRNA counts in p53wt cell lines as indicated by 
negative shRNA scores.  
shRNA scores were collapsed into gene scores using KS statistics. Genes on top of the ranking 
list had lower shRNA counts in p53wt cell lines and genes on the bottom had lower shRNA 
counts in p53mut cell lines (Figure 21B). The most robust candidates were selected by 
stringent filtering criteria as described in section 3.5.6. In brief, we selected genes with at least 
two significantly underrepresented shRNAs and significantly lower (p<0.05), negative gene 
depletion scores (weighted z-score (wZ)<-0.5) in p53wt cell lines. We removed genes that were 
not found to be expressed in RNA sequencing or that scored with shRNAs that had overlapping 
target regions. Twelve genes were fullfilling all criteria (Figure 21C). Four of these genes were 
also essential in p53mut cell lines (wZ-score<-0.5), but significantly stronger depleted in p53wt 
cell lines. These included two metabolic genes (GALNTL4, CYP39A1), one methyltransferase 
(BHTM2) and one histone subunit (HIST3H3).  
The p53 inhibitor MDM4 was identified as the strongest gene specifically essential in p53wt 
cell lines. MDM4 is located on 1q32. As chr1q gain was associated with p53wt BL patients (see 
section 4.1), we wanted to know if genes on chr1q were more essential in p53wt cell lines. 
Figure 21D shows the median gene depletion scores in p53wt versus p53mut cell lines. The shRNA 
library covered 237 genes located on chr1q (indicated in dark grey). We did not observe a p53-specific 
dependence of chr1q genes. Besides of MDM4, the cell cycle regulator CDKN3 (rank 8) was the strongest 
outlier here and both genes were chosen for validation. 
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Figure 21: Identification of essential genes specific to p53wt BL cell lines.  
(A) Ranking of shRNAs by differential representation in 4 p53wt vs. 4 p53mut cell lines. RPL30 
(essential) and APOA4 (non-essential) are shown as controls. MDM4 and CDKN3 were two 
candidate genes chosen for validation. (B) Ranking of p53-specific essential genes. Low ranking 
genes showed lower shRNA counts in p53wt and high ranking genes had lower counts in 
p53mut. (C) Overview of 12 high-reliability candidate genes essential specifically in p53wt cell 
lines. The list shows the gene score and the median wZ-score calculated over 4 p53wt or 4 
p53mut cell lines. (D) Median wZ-score over 4 p53wt and 4 p53mut cell lines with indicated 
common essential genes (grey triangle), genes on chr1q (grey dots), 12 high-reliability 
candidates (green dots), control APOA4 (non-essential) and RPL30 (essential) and MDM4 and 
CDKN3 chosen for validation. 
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4.3 MDM4 depletion induces p53-dependent cell cycle arrest  
4.3.1 Validation of RNAi screening 
To validate the observed phenotype we first tested the effect of shMDM4_1–5 on MDM4 
mRNA and protein level. After lentiviral delivery of targeted shRNAs or shNT transduced cells 
were selected with puromycin to ensure that >90% of cells carry the shRNA vector. MDM4 
mRNA level were quantified using RT-qPCR and protein level were determined in immunoblot 
analysis (Figure 22A, B). All shRNAs led to a significant downregulation of MDM4 mRNA and 
protein level between 40-60%.  
 
Figure 22: On-target effect of shRNAs directed against MDM4. 
Quantification of MDM4 level in the BL-2 cell line 5 days after transduction with 5 shRNAs 
targeting MDM4 and a non-targeting control shNT. (A) mRNA level of MDM4 and GAPDH were 
determined by quantitative real-time PCR. The expression values were normalized to the 
house keeping gene GAPDH and to shNT. The error bars indicate the mean standard error of 
three independent biological replicates. ***=p-value<0.001 (B) Immunoblot analysis for 
MDM4 and GAPDH. MDM4 protein expression was normalized to GAPDH and shNT. 
 
We tested the effect of MDM4 depletion on cell viability and proliferation in an RFP-
competition assay. Cells were transduced with lentiviral shRNA vectors at ~50% and co-
expressed RFP. Essential genes were identified by loss of RFP-signal as quantified by flow 
cytometric analysis (Figure 23A). For validation experiments we extended the panel of BL cell 
lines. Besides of the eight BL cell lines from the screen, four additional p53mut cell lines were 
included. Two shRNAs located in different exons of MDM4 (shMDM4_1: spanning exon 3-4 
boundary; shMDM4_2: exon 7) were chosen for validation. Three out of four p53wt cell lines 
showed strong depletion of RFP signal, indicating toxicity of the target gene knock-down 
(shMDM4_1: Ø17%; shMDM4_2: Ø35%), while all p53mut cell lines showed moderate effects 
to MDM4 depletion (shMDM4_1: Ø74%; shMDM4_2: Ø81%) (Figure 23B). The p53wt BL-2 cell 
line was insensitive towards MDM4 knock-down and behaved like a p53mut cell line 
(shMDM4_1: 76%; shMDM4_2: 85%). Comparison of RFP depletion in single knock-down 
experiments with loss of shRNA counts in the RNAi screen showed high reproducibility 
confirming the robustness of the RNAi screen (Figure 23C). 
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Figure 23: RFP competition assay after MDM4 depletion. 
(A) Exemplary plots from flow cytometric analysis of RFP-signal in cells transduced with toxic 
shRNAs. The upper plot shows the RFP-signal on day 3 post-transduction and the lower plot on 
day 14. (B) Relative RFP-signal over 14 days in 12 BL cell lines transduced with shMDM4_1 and 
shMDM4_2 (green: p53wt, rest: p53mut). The RFP-signal was fully established between day 3 
and day 5 post-transduction and all RFP-values were normalized to the maximal expression. (C) 
Loss of RFP-signal in single knock-down experiments and depletion of shRNA counts in the 
RNAi screen on day 14 post-transduction. (green: p53wt; red/orange: p53mut) 
 
4.3.2 Generation and characterization of a p53 knock-out model 
To test if effects seen after MDM4 depletion depend on p53, we generated an isogenic p53 
knock-out (p53ko) cell line from p53wt Seraphine using the CRISPR/Cas9 technology. In a one-
vector system, the microbial endonuclease Cas9 was co-expressed with single-guide RNAs 
(sgRNA) targeting TP53 in exon 4 (sgRNA#1), exon 5 (sgRNA#2) or exon 7 (sgRNA#3). The 
sgRNAs bind to their complementary sequence on the genomic DNA and direct Cas9 to the 
desired target region. Cas9 induces double strand breaks that are repaired by error-prone non-
homologous end joining (NHEJ). As a result, deletions and, in rare cases, insertions are 
introduced that lead to a loss of gene function.  
We tested the efficiency of disrupting p53 function of three independent guide RNAs targeting 
different exons. Cells transduced with CRISPR/Cas9 expression vectors co-expressed a 
puromycin resistance gene and were first selected with puromycin. To remove clones still 
carrying functional p53 protein (either by lack of a cut or in-frame deletions), cells were 
propagated in the presence of the small molecule inhibitor nutlin-3, that induces p53-
dependent apoptosis by MDM2 inhibition. All three sgRNAs conferred resistance towards 
nutlin-3 indicating inactivation of p53 (data not shown). For further studies we selected the 
Seraphine cell line infected with sgRNA#1. We confirmed the presence of deletions in p53 exon 
4 using a DNA mismatch repair assay (Figure 24). As NHEJ introduces various random 
deletions, efficient targeting of TP53 results into a pool of cells carrying different mutations. 
After DNA extraction and amplification of the genetic locus, DNA double strands were 
denatured and re-annealed in a thermocycler. Annealing between the original DNA strand and 
a shorter strand carrying a deletion leads to formation of a loop. The T7 endonuclease cuts the 
A B C 
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DNA at the site of the loop and produces fragments of various sizes (Figure 24A). In the 
parental p53wt cell line addition of the T7 endonuclease to the PCR product resulted into two 
smaller bands besides of the full length PCR product (581bp) (Figure 24B). The same pattern 
was seen for sgRNA#2 and sgRNA#3 that target different exons. For sgRNA#1, which targets 
the amplified region, three bands with a unique pattern were observed.  
Figure 24: Generation and characterization of a p53 knock-out cell line 
(A) Schema of the mismatch repair assay. The target sequence of the sgRNA was amplified 
from genomic DNA of a mixed pool of cells carrying different deletions (a=full-length, b=short 
deletion, c=long deletion). After denaturing and re-annealing of the DNA double strands, loops 
were forming at the sites of missing base pairs that were targeted by T7 endonuclease. (B) 
Mismatch repair assay in Seraphine cell line. The exon 4 of TP53 was amplified from the 
parental p53 wild-type (wt) cell line or modified cell lines expressing sgRNA#1, #2 or #3 and 
either left untreated (-) or incubated with T7 endonuclease (T7).  
 
The p53ko cell line was included in a compound screen on 28 cell lines (including 18 BL cell 
lines) that was performed by Marina Lukas and Katarzyna Tomska. Nutlin-3 that was also 
included in the screen showed the strongest p53-specific toxicity. All p53wt cell lines were 
sensitive towards nutlin-3 starting from a concentration of 3µM, while p53mut and the p53ko 
cell lines did not respond to concentrations up to 10µM (Figure 25A). The toxicity that can be 
seen at 30µM might be explained by unspecific effects or by disruption of the p73-MDM2 
binding137. Using flow cytometry we analyzed p53 protein level in the p53wt and the p53ko cell 
line treated with nutlin-3 or dissolvent (DMSO) after intracellular staining with fluorophore-
labeled antibodies (Figure 25B). The basal expression level of p53 was lower in the p53ko cell 
line and nutlin-3 treatment increased p53 level in the p53wt, but not in the p53ko cell line. 
Accordingly, nutlin-3 induced apoptosis in the p53wt, but not in the p53ko isogenic cell line as 
shown in flow cytometry using APC-labeled Annexin V to stain the membrane of apoptotic cells 
and 7-AAD to stain exposed DNA of dying cells. 
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Figure 25: Nutlin-3 treatment of the p53ko cell line 
(A) Titration of nutlin-3 in 18 BL cell lines (7 p53wt, 1 p53ko, 10 p53mut). All cell lines were 
incubated with 10 different concentrations of nutlin-3, DMSO or PBS for 48h. Cell content was 
measured by ATP level using a luminescent assay and normalized to DMSO. The curves were 
generated with a non-linear fit. The data was kindly provided by Katarzyna Tomska. (B) Flow 
cytometric analysis of p53 level after intracellular staining. Seraphine p53wt and p53ko cells 
were grown in the presence of 10µM nutlin-3 or 0.1% DMSO for 10h. Cells were fixated and 
permeabilized for intracellular staining using a p53-antibody coupled to the fluorophore FITC. 
(C) Flow cytometric analysis of apoptotic cells after nutlin-3 treatment. Seraphine p53wt and 
p53ko were incubated with 10µM nutlin-3 or DMSO (0.1%) for 10h. Early apoptotic and dead 
cells were stained with Annexin V-APC and 7-AAD. 
 
To test if cytotoxic effects of MDM4 knock-down were p53-dependent we performed the RFP 
competition assay in the isogenic p53ko and p53wt cell lines. shNT was stably expressed in 
both cell lines. In the p53wt cell line, 80% of cells expressing shMDM4_2 were lost 14 day post-
transduction, while cells of the p53ko cell line were unaffected. shMDM4_1 showed strong 
cytotoxic effects in the p53wt cell line. 56% of cells were depleted after 7 days and 90% after 
14 days. In the p53ko cell line the effect of shMDM4_1 was much weaker. 10% of RFP-positive 
cells were lost on day 7 and 56% on day 14, suggesting p53-dependent cytotoxicity. 
Figure 26: MDM4 knock-down in the p53ko cell line 
RFP-competition assay in Seraphine-p53wt (green) and Serapine-p53ko (blue) after MDM4 
knock-down. Isogenic Seraphine cells were infected with shNT, shMDM4_1 or shMDM4_2 at 
an infection rate of ~50% and infected cells were monitored in flow cytometry by RFP 
expression over 14 days. Fraction of RFP-positive cells was normalized to day 3. 
A C 
p53wt 
DMSO 
p53wt 
Nutlin 
p53ko 
DMSO 
p53ko 
Nutlin 
-6 -4 -2 0 2 4 6
0
20
40
60
80
100
120
p53mut
p53wt
p53ko
log2 (concentration) [µM]
%
 o
f 
v
ia
b
ili
ty
fr
o
m
 D
M
S
O
 c
o
n
tr
o
l
Annexin-V-APC 
7
-A
A
D
 
30% 
Nutlin-3 
Nutlin-3 
p53ko 
p53wt 
9% 
7% 
5% 
DMSO 
DMSO 
B 
p53-FITC 
3 6 9 12 15
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Seraphine-p53wt
Seraphine-p53ko
shMDM4_1
shMDM4_2
shNT
day
R
e
la
ti
v
e
 R
F
P
-p
o
si
ti
v
e
 c
e
ll
s
Results 68  
4.3.3 Cell cycle analysis after MDM4 depletion 
MDM4 depletion did not induce apoptosis (data not shown). Therefore, we analyzed the effect 
of MDM4 knock-down on the cell cycle profile in the presence or absence of functional p53. In 
Seraphine-p53wt and Seraphine-p53ko 28% and 27%, respectively, incorporated BrdU into 
their genomic DNA within 3h of culturing, while 62% of Raji (p53mut) cells were BrdU-positive 
(Figure 27A). In the p53wt cell line both shRNAs targeting MDM4 led to a ~50% decrease in 
cycling cells compared to shNT, while no significant effect was seen in the p53mut cell line 
(Figure 27B). In the p53ko cell line, shMDM4_2 had no effect on the cell cycle and shMDM4_1 
induced a moderate G1 arrest of about 20%, in line with the results from the RFP competition 
assay. In immunoblot analysis of the p53wt cell line following MDM4 knock-down we detected 
increased expression of p53 with both shRNAs (1.4/1.7) and p53 target genes p21 (1.3/1.3) and 
PUMA (1.6/1.5), but not PARP cleavage that would indicate apoptosis.  
Figure 27: p53-mediated cell cycle arrest after MDM4 knock-down 
(A) Exemplary plots from flow cytometric analysis of cell cycle phases in p53wt, p53ko and 
p53mut cell lines. Cells were grown in the presence of the nucleotide analogue BrdU that was 
incorporated into cycling cells. After cell fixation and permeabilization BrdU was stained with 
APC-labeled antibody. Total DNA amount was stained with 7-AAD. orange = G1-phase, violet = 
S-phase, blue = G2/M phase, grey = Sub-G1-phase. (B) Quantification of cells in the DNA 
synthesis phase (S-phase). The bars represent triplicate measurements of cell fractions in the 
S-phase normalized to shNT. (C) Immunoblot analysis in Seraphine-p53wt transduced with 
shNT, shMDM4_1 and shMDM4_2. Protein levels were normalized to GAPDH and to shNT. 
Cleaved PARP was not detected above background and could not be quantified. 
 
4.3.4 The MDM4 homologue MDM2 shows similar effects on cell cycle progression 
The p53 inhibitor MDM2 shares a similar structure with MDM4 and both proteins are needed 
to suppress p53. In our screen MDM2 was not identified as a p53-specific essential gene. To 
investigate the role of MDM2 in p53wt BL, we analyzed the effect of MDM2 targeting shRNAs 
in the screen (Figure 28). One out of five shRNAs (shMDM2_1) was underrepresented in the 
p53wt group (Figure 28A). After collapsing of all shRNAs into gene scores MDM2 showed a 
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tendency towards p53wt-specific toxicity (p=0.05, Figure 28B). As this score was driven by a 
single shRNA, MDM2 was not considered as a candidate gene. We tested the on-target effect 
of all 5 shRNAs on mRNA and protein level (Figure 28C). To avoid MDM2 upregulation by 
activation of the p53-dependent negative feedback loop, the p53ko cell line was chosen. 
MDM2 mRNA and protein level were reduced by two shRNAs, shMDM2_1 (27%/35%) and 
shMDM2_3 (54%/53%). To conclude, the shRNA that gives the strongest on-target effect on 
MDM2 was specifically toxic in p53wt, but not p53mut BL cell lines. The gene MDM2 did not 
score in the screen due to lack of on-target effect for most shRNAs.  
 
Figure 28: MDM2 knock-down in the RNAi screen 
(A) shRNAs from the RNAi screen ranked by differential representation in p53wt vs. p53mut 
cell lines. shRNAs 1-5 targeting MDM2 are highlighted. shRNAs with negative shRNA scores 
were underrepresented in p53wt cell lines. (B) Genes ranked by differential shRNA 
representation. Genes with significantly lower shRNA counts in p53wt cell lines are marked in 
light green (p-value<0.01) and dark green (p-value<0.05). (C) Protein and mRNA level of MDM2 
in Seraphine-p53ko cell line 3 days after lentiviral delivery of shNT or shMDM2_1-5. More than 
80% of cells were RFP-positive. MDM2 mRNA level were determined in RT-qPCR and protein 
level in immunoblot analysis. All values were normalized to GAPDH and to shNT. (D) RFP 
competition assay in all eight screening cell lines. Cells were transduced with shNT, shMDM2_1 
or shMDM2_3 at ~50% transduction rate and RFP-signal was measured over 14 days. Fraction 
of RFP-positive cells was normalized to day 5 post-transduction. (E) Cell cycle profiling in 
Seraphine-p53wt, Seraphine-p53ko and Ramos (p53mut) transduced with shNT or shMDM2_1. 
Cells were fixated and permeabilized. Total DNA was stained with 7-AAD and measured in flow 
cytometric analysis. Cells in G1-phase, Sub-G1-phase and S-G2-M-phase were quantified. 
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To test if MDM2 is essential in BL cell lines with or without functional p53 we performed the 
RFP competition assay in all screening cell lines using both shRNAs with confirmed on-target 
effect (Figure 28D). shMDM2_1 showed strong viability effects in all p53wt cell lines (Ø44%), 
but not in p53mut cell lines (Ø78%). shMDM2_3 was depleted in 3/4 p53wt cell lines (Ø55%), 
but also in 2/4 p53mut cell lines (Ø60%). We tested the effect of MDM2_1 on the cell cycle of 
the isogenic Seraphine cells and Ramos (p53mut) (Figure 28E). Total DNA was stained with      
7-AAD after permeabilization of cell that either expressed shNT or shMDM2_1. The p53wt cell 
line showed a reduction of cycling cells of 9% after MDM2 depletion, while 4% and 5% 
reduction was observed in the p53ko and p53mut cell line, respectively.  
 
4.3.5 Basal expression of MDM4 and MDM2 in BL cell lines 
To see if vulnerabilities towards MDM2 and MDM4 depletion correlated with protein and/or 
mRNA abundance, we used qPCR and immunoblot analysis to determine the basal expression 
levels of p53, MDM2 and MDM4 in all screening cell lines and eight additional BL lines. In total, 
our analysis included 8 p53wt and 8 p53mut BL cell lines (Figure 29). In p53wt cell lines, we 
observed low or undetectable levels of p53 protein. Under physiologial conditions, p53 protein 
levels are tightly regulated and protein levels are kept low by rapid proteasomal turnover. 
Mutant p53 is resistant towards MDM2-mediated proteasomal degradation and therefore 
accumulates in the cell. This is in accordance with our observations in BL cell lines. All p53mut 
cell lines showed high p53 protein expression. Protein levels were not correlated with mRNA 
level in either group. Most p53mut cell lines expressed low p53 mRNA, while about half of 
p53wt cell lines showed elevated level. 
 
Figure 29: Basal expression of p53, MDM2 and MDM4 in BL cell lines 
(A) Correlation of protein and mRNA for p53, MDM4 and MDM2 in p53wt (green) and p53mut 
(red) BL cell lines. (B) Immunoblot for p53, MDM2 and MDM4 in 8 p53wt (green) and 8 
p53mut (red) BL cell lines. GAPDH was used as a control. 
 
For MDM4, we observed a significant correlation between mRNA and protein level (Figure 
29B). Most cell lines with high expression level belonged to the group of p53wt cell lines (4 out 
of 5). For MDM2, protein expression levels were low in most cell lines and not correlated with 
mRNA. BL-2 (p53wt) was the only cell line with high MDM2 mRNA and protein level. In 
addition, BL-2 expressed high MDM4, while most p53wt cell lines expressed either high MDM2 
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(Seraphine) or MDM4 (Salina, DogKit and Gumbus). MDM4 and MDM2 expression level did not 
correlate with sensitivity towards protein depletion.  
 
4.3.6 Gene expression profiling after MDM4 and MDM2 knock-down 
To determine the signaling pathways that were influenced by depletion of MDM4 and MDM2 
we performed gene expression profiling in the Seraphine-p53wt and Seraphine-p53ko cell line 
after MDM4 and MDM2 knock-down. Cells were transduced at high infection rates (>80% RFP+ 
cells) with shNT, two shRNAs targeting MDM4 (shMDM4_2, shMDM4_3) and one shRNA 
targeting MDM2 (shMDM2_1, the only validated shRNA showing strong on-target effect and 
p53-specific viability effects). On day 5 post-transduction RNA was extracted and hybridized on 
an Illumina BeadChip. In all samples ~16,700 gene probes (corresponding to ~13,000 genes) 
were found to be expressed above the background signal. MDM4 and MDM2 expression could 
not be detected, because of the low resolution of the assay. Therefore, depletion of the target 
gene was validated by qPCR (Figure 30A). shRNAs targeting MDM4 efficiently depleted MDM4 
mRNA in both cell lines (shMDM4_2: 0.3; shMDM4_3: 0.4) and increased MDM2 level 
exclusively in the p53wt cell line (shMDM4_2: 2.5; shMDM4_3: 2.7). shMDM2_1 efficiently 
reduced MDM2 level in the p53ko cell line (0.4). The on-target effect was not visible in the 
p53wt cell line (1.1). As mentioned previously, the p53-dependent negative feedback loop 
might lead to an upregulation of MDM2 mRNA. 
The p53wt cell line showed more dynamic changes of the gene expression (90-560 gene 
probes with at least 2-fold difference) compared to the p53ko cell line (1-120 gene probes with 
at least 2-fold difference) (Figure 30B). shMDM4_3 showed the strongest effects on gene 
expression, in the p53wt as well as the p53ko cell line. This may indicate p53-independent 
effects specific to this shRNA. 
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Figure 30: Gene expression profiling after MDM4 and MDM2 knock-down 
(A) Relative mRNA level of MDM4 (left) and MDM2 (right) in Seraphine-p53wt (green) and 
Seraphine-ko (blue) transduced with the indicated shRNAs. mRNA levels were normalized to 
shNT. (B) Gene expression values in Seraphine-p53wt and Seraphine-p53ko transduced with 
shMDM4_2, shMDM4_3, shMDM2_1 or shNT. Genes with more than two-fold increase (red) 
or decrease (blue) are indicated. Gene probes of the respective targets, MDM4 or MDM2, are 
shown in green. Gene probes in the range of background noise (p-value>0.05, mean 
expression value<110) are marked in grey. 
 
We tested if genes within pre-defined gene sets were specifically deregulated. Using gene set 
enrichment analysis (GSEA) the distribution of genes within hallmark sets was compared to the 
overall distribution of the data and an enrichment score (ES) was calculated. Figure 31A shows 
the results from GSEA for shMDM4_2 as an example. p53 target genes showed the strongest 
ES (0.55) for upregulated genes. Downregulated genes were strongly enriched for genes in key 
pro-survival and proliferation pathways including E2F targets (ES=-0.63), G2M checkpoint (ES= 
-0.51) and MYC targets (ES=-0.54). The same pathways were significantly deregulated by 
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shMDM4_3 and shMDM2_1 (Figure 31B). To validate these findings, we measured mRNA level 
of selected p53 target genes and cell cycle regulators following MDM4 knock-down 
(Figure31C). MDM4 was stably repressed between days 3 and 5. p53 targets MDM2, p21, BAX 
and RRM2B were about 1.5-fold elevated on day 3 after transduction of cells with shMDM4_2 
and further increased up to 2-fold on day 5, while p53 mRNA level remained unchanged. To a 
similar extent, cell cycle regulators of the MCM-family were depleted between days 3 and 5. 
CDKN3 level were unchanged on day 3 and 4, but rapidly decreased on day 5.  
 
Figure 31: GSEA for differentially expressed genes following MDM4 and MDM2 depletion 
(A) Gene set enrichment analysis (GSEA) for differential gene expression in Seraphine-p53wt 
transduced with shNT or shMDM4_2. The graphs were generated with software provided by 
the Broad Institute. All genes were sorted by their fold-change from genes higher in 
shMDM4_2 (red) to genes lower in shMDM4_2 (blue). Based on the distribution of shRNAs 
within respective gene sets (black bars), an enrichment score (ES) was calculated. (B) ES for 
hallmark pathways. Positive ES = upregulation; negative ES = downregulation. (C) Time course 
of mRNA level in Seraphine-p53wt infected with shMDM4_2 for p53 targets (green), cell cycle 
regulators (blue) and shRNA target (red). (D) Overlap of the 300 most up- or downregulated 
genes between three shRNAs. (E) Heatmap for commonly regulated genes.  
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The observation that MDM4 knock-down represses CDKN3 is interesting as p53wt cell lines 
were specifically dependent on CDKN3 in the RNAi screen. To investigate genes that were 
commonly regulated after MDM4 or MDM2 knock-down we selected the 300 most up- and 
downregulated genes in either sample and compared the overlap (Figure 31D). 37 genes were 
among the most downregulated genes with either shRNA, while 51 genes were commonly 
upregulated. The fold-changes of commonly regulated genes are shown as a heatmap in Figure 
31E. 
 
4.3.7 MDM4 depletion in a mouse xenograft model 
To evaluate if MDM4 serves as a potential target in tumor therapy the influence of MDM4 
depletion on xenograft formation in mice was tested. shMDM4_2 was used to knock-down 
MDM4 in isogenic Seraphine cell lines (p53wt, p53ko) and in Raji (p53mut). The non-targeting 
control shNT was used as a reference. After transduction and puromycin selection, shRNA 
expressing cells were injected subcutaneously into the left (shMDM4_2) or right (shNT) flank 
of three mice per cell line. For quantification of tumor growth the metabolic activity of the 
tumor cells in the xenograft was determined by uptake of the glucose analogue 
fluordesoxyglucose (FDG) using positron emission tomography (PET) (Figure 32A). Tumor size 
was also measured after sacrificing of the mice (Figure 32B). In the p53wt cell line tumor 
growth was significantly reduced after MDM4 knock-down, compared to the control shRNA 
(average 59%, p<0.05). Tumors were also smaller post-mortem (73%).  
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Figure 32: MDM4 knock-down decreases xenograft formation in mice. 
(A) Exemplary figures of the FDG-PET scanning. The white arrows mark the tumor xenograft. 
The graph shows the quantification of FDG-uptake with error bars indicating the mean 
standard error of three mice. (B) Exemplary figures of excised tumors of sacrificed mice. The 
graph shows the quantification of tumor size. Error bars show the mean standard error of 
three mice. The experiment was performed in collaboration with Dr. Stefan Habringer in the 
research group of Professor Dr. Ulrich Keller (Medical clinic III, Munich, GER). 
 
4.3.8 MDM4 dependence across p53wt cancer cell lines  
To test if p53-specific dependence on MDM4 is limited to BL cell lines, we re-analyzed a 
publically available loss-of-function RNAi screen in 216 cell lines representing 19 tumor 
entities112. On a genome-wide scale the Broad Institute screened 54,020 shRNAs from the TRC 
library targeting ~11,000 genes. Based on the COSMIC data base (Sanger Institute, 
http://cancer.sanger.ac.uk/cosmic) and published RNA sequencing data133 we could determine 
the p53 status for 158 cell lines. 77 cell lines carried p53 mutations (49%) and 81 cell lines were 
p53 wild-type (51%) (Figure 33A).  
We ranked the genes according to their differential shRNA representation in both groups. 
MDM4 showed significant underrepresentation of shRNAs in p53wt cell lines and was 
identified on rank 20 (p<0.001) (Figure 33C). For seven tumor entities at least 4 cell lines were 
available per group which allowed an analysis for p53-specific gene dependences in single 
entities (CNS, haematopioetic&lymphoid, ovary, lung, large intestine, pancreas, breast) (Figure 
33B). The strongest association was found in large intestine (rank 7, p<0.001) and ovary 
carcinoma cell lines (rank 173, p=0.01) (Figure 33D). In a comparison of common p53-specific 
essential genes identified in both our BL screen and the Achilles project we also found the cell 
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cycle regulator CDKN3 (rank=127, p=0.01). However, CDKN3 was not significantly associated 
with p53 status in entity-specific analysis. 
 
Figure 33: p53-specific gene dependences across cancer 
(A) Number of cell lines from the Achilles Project v2.4.3 with available p53 mutation status 
(Broad Institute)112. (B) Representation of cancer entities with indicated p53 mutation status. 
(C) Ranking of genes by differential shRNA representation in p53wt vs. p53mut cell lines. 
Genes marked in green show significantly lower shRNA counts in p53wt cell lines (p≤0.01). Two 
candidate genes (MDM4 and CDKN3) and p53-independent control genes are indicated. (D) 
Depletion of shRNAs targeting MDM4 in 9 p53wt (green) and 9 p53mut (red) large intestine 
cell lines. 
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4.3.9 BL patients express a strong p53 signature 
To study the effect and function of p53 mutation on cellular pathways, we generated a 
molecular signature for mutant p53 based on differentially expressed genes in 430 B-NHL 
primary samples where gene expression data was available (MMML). Data analysis was 
performed by Dr. Maciej Rosolowski and Dr. Markus Kreuz (Interdisciplinary Centre for 
Bioinformatics, University of Leipzig, GER). Samples from mBL, non-mBL and intermediate 
patients (as defined by Hummel et al., 2006) were grouped by p53 mutation status to derive a 
p53 mutant signature across all patients (Figure 34A). The signature includes 50 gene probes 
with the highest reliability of higher or lower expression, respectively, in p53mut compared to 
p53wt patients. 
Genes expressed higher in p53mut patients were not enriched for hallmark gene sets. 
Interestingly, the gene CDKN2A, encoding for the tumor suppressors p14ARF and p16INK4a, 
showed the strongest differential expression with two gene probes (Figure 34B, left). CDKN2A 
is often deactivated in cancers without p53 mutations, either by deletion or hypermethylation. 
In BL, deletion of the CDKN2A locus on chr9p21 is rare. Therefore, alternative mechanisms 
must exist. Unfortunately, methylation data was only available on a limited number of patients 
and we could not test an association of CDKN2A methylation status and p53 mutation. 
Genes expressed lower in p53mut patients were strongly enriched for p53 target genes (n=9; 
MDM2, BAX, RPS27L, TNFRSF10B, TRIM22, DDB2, CCNG1, CDKN1A, FDXR) (Figure 34B right, C). 
These data suggest that a portion of B-NHL retain active p53 signaling. This finding allowed us 
to query both disease specific differences and measure activity of p53 pathway activation in 
the context of wild-type and mutant p53.  
In addition, gene set enrichment analysis for chromosomal regions identified genes on 17p13 
(n=11) and 1q32 (n=3) (Figure 34B right, C) associated with p53 status. This effect might reflect 
gene dosage effects. Loss of 17p13 mainly affects p53mut patients and results into decreased 
expression of genes within this locus. Gain of 1q32 associates with p53wt and results into 
increased expression in p53wt patients. As shown in Figure 34D, elevated expression of MDM4 
and RNPEP was specifically observed in BL, but not in non-BL patient samples. While MDM4 
level in p53mut BL were comparable to either p53wt or p53mut non-BL, p53wt BL expressed 
higher level (Figure 34E). At the same time, p53 target genes were stronger activated in p53wt 
non-BL (Figure 34F, G).  
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Figure 34: p53 gene expression signature 
(A) Supervised hierarchical clustering of differentially expressed gene probes in 430 B-NHL. 
Every column represents a patient and every row represents a gene. Patients were clustered 
by molecular diagnosis into intermediate (grey), BL (red) and DLBCL (blue) and by p53 status 
into mutant (red) and wild-type (blue). Deletion of chr17p13 and gain of chr1q32 are indicated 
(black=mutation, grey=normal, white=unknown). 50 gene probes higher (red) or lower (blue) 
in p53mut were sorted by their strength to differentiate between the groups with the 
strongest discriminators on the bottom. (B) Fold-changes for 50 gene probes expressed lower 
(left) or higher (right) in p53mut samples. (C) Genes from the 50 gene probes expressed lower 
in p53mut were tested for enrichment in hallmark gene sets and chromosomal positions. (D) 
Differential expression of genes on chr1q32 in BL and non-BL samples. (E) Expression of MDM4 
in BL and non-BL samples with and without p53mut. (F) Differential expression of p53 targets 
in BL and non-BL samples. (G) Exemplary expression of p53 targets in BL and non-BL.   
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4.4 p53-specific effects of the cell cycle regulator CDKN3 
The dual-specificity phosphatase CDKN3 controls the spindle checkpoint and is needed to 
ensure correct chromosomal segregation during mitosis. In our RNAi screen CDKN3 knock-
down was toxic exclusively to p53wt BL cell lines. Using RT-qPCR we confirmed depletion of 
CDKN3 mRNA by all of the six shRNAs included in the shRNA library (Figure 35A). Validated 
antibodies for CDKN3 were lacking. Therefore, the on-target effect on protein level could not 
be tested. We selected two shRNAs and performed the RFP-assay as described above to 
validate the phenotype observed in the RNAi screen. All eight screening cell lines and the 
isogenic p53ko cell line were transduced with lentiviral vectors and transduced cells were 
monitored for RFP-expression over 14 days using flow cytometry (Figure35B, C). Both shRNAs 
were depleted stronger in p53wt cell lines compared to p53mut cell lines (p53wt: Ø 37%, 
p53mut: Ø 64%, p<0.05). shCDKN3_5 that was toxic in the Seraphine-p53wt cell line (30%) 
showed limited effect in the Seraphine-p53ko line (70%). shCDKN3_6 was toxic to both cell 
lines, but exerted a stronger effect in the p53wt cell line (p53wt: 16%, p53ko: 24%). To study 
the effect of CDKN3 depletion we performed cell cycle profiling in the isogenic Seraphine lines 
and Ramos (p53mut). After CDKN3 knock-down using two independent shRNAs total DNA 
amount was stained by 7-AAD and measured in flow cytometry (Figure 35D). After CDKN3 
depletion Seraphine-p53wt showed an arrest in the G1-phase and a reduction of cycling cells 
(54%). This effect was not observed in the p53mut cell lines (93%) and the p53ko cell lines 
(88%). 
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Figure 35: Depletion of CDKN3 induces G1-arrest in p53wt BL 
(A) mRNA level for CDKN3 were measured by RT-qPCR in the Seraphine-p53ko cell line infected 
with shNT or shCDKN3_1-6. The measurements were performed in triplicates. Error bars 
indicate the mean with standard deviation. (B) Relative RFP-signal in cells transduced with two 
shRNAs targeting CDKN3. In a partially transduced cell culture the fraction of RFP+/shRNA+ 
cells was normalized to day 3. red=p53mut, green=p53wt (C) Comparison of RFP-signal 
depletion in the isogenic Seraphine cell lines. green=p53wt, blue=p53ko; (D) Cell cycle profiling 
in isogenic Seraphine and Ramos (p53mut). Total DNA was stained in fixated cells using 7-AAD.  
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4.5 Entity-specific essential genes 
We performed an RNAi screen in a large panel of BL cell lines (n=8) and could robustly identify 
general as well as genotype-specific essential genes. BL cell lines were not represented in the 
Achilles project and according to our knowledge this is one of the largest genetic perturbation 
screens in BL. Therefore, we asked if our data could also help to predict specific vulnerabilities 
in B-cell lymphoma or Burkitt lymphoma. The provider of the DECIPHER Module 1 library 
(Cellecta Inc., Mountain View, CA, USA) generated RNAi screening data in 12 cell lines 
representing seven different entities (Table 3). The data can directly be compared to our RNAi 
screening data in BL, because the same library and protocols were used.  
Table 3: Cell lines used in external RNAi screens  
List of pooled shRNA screens performed by Cellecta company. 
Screen Cell lines Entity # of replicates Time-point Library version 
HDM1_p23 
K562 CML-myeloid 4 9 days 
NA Jurkat ALL T-lymphocyte 4 9 days 
DU-145 Prostate carcinoma 3 8 days 
HDM1_v1 
MDA-MB-231 Breast carcinoma 3 11 days 
pRSI9 
A2780 Breast carcinoma 3 10 days 
HDM1_v2 
C4-2 Prostate carcinoma 3 8 days 
pRSI12 
R22v1 Prostate carcinoma 3 8 days 
PC3 Prostate carcinoma 3 8 days 
THP1_RPCI Monocyte 3 9 days 
THP1_ATCC Monocyte 3 10 days 
U937 DLBCL 3 10 days 
AML19310 AML myeloid 3 10 days 
 
We applied the same analysis pipeline as described for our own screen to data from Cellecta. 
As no sequencing data was provided for early time points after infection, shRNA counts were 
normalized to their abundance in the respective plasmid libraries. shRNA fold-changes for all 
screens were combined and normalized for differences in data dispersion between cell lines 
(Figure 36A). In a class comparison approach, we identified genes with significantly lower 
shRNA counts in BL cell lines (n=8) compared to non-lymphoid cell lines (prostate and breast 
carcinoma, n=6) (Figure 36B, left). We then further selected candidate genes by the strength of 
shRNA depletion. For this, we calculated the median over the logarithmic fold-change for 
respective cell line groups (Figure 36B, right). Common essential genes showed strong shRNA 
depletion in all three groups, while non-essential genes were unchanged. 
Among the genes essential specifically in BL we identified PAX5, that plays an important role in 
B-cell differentiation, and the proto-oncogene FLI1, that was first described in 
erythroleukemias. PAX5 was among the 50 most essential genes in BL (rank=46; median 
log2(fold-change)=-2.03), while its knock-down did not affect non-lymphoid cell lines 
(rank=2663; median log2(fold-change)=-0.31). FLI1 was on rank 169 of toxic genes in BL 
(median log2(fold-change)=-1.47), but was dispensable in non-lymphoid lines (rank=2186; 
median log2(fold-change)=-0.41).  
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Both transcription factors are mainly expressed in cells of the lymphoid lineage. To further 
investigate if candidate genes play a specific role in the pathogenesis of Burkitt lymphoma, we 
repeated the analysis as described above comparing essential genes in BL with essential genes 
in five hematopoietic-lymphoid, non-BL cell lines. PAX5 was again identified as a gene with 
significant lower shRNA counts in BL (Figure 36C, left). Depletion of PAX5 did not have an effect 
in hematopoietic-lymphoid cell lines (rank=2186; median log2(fold-change)=-0.41) (Figure 36C, 
right). shRNAs targeting FLI1 were also strongly depleted in hematopoietic-lymphoid cell lines, 
specifically in the three lymphoid lines (rank=132; median log2(fold-change) =-1.6) and 
therefore FLI1 did not score in the comparison for genes with differential shRNA 
representation. In addition, we could also identify genes (e.g. ALLC) that were essential in BL 
and some non-lymphoid cell lines, but not in hematopoietic-lymphoid cell lines. Figure 36D 
shows the logarithmic fold-changes for all shRNAs targeting PAX5, FLI1 or ALLC in BL, 
hematopoietic-lymphoid and non-lymphoid cell lines. 
 
Figure 36: Identification of entity-specific gene dependences 
(A) PMAD (peak median absolute deviation) normalization of logarithmic fold-changes for cell 
lines from our own RNAi screen and RNAi screens provided by Cellecta. (B) left: Analysis of 
genes with differential shRNA representation in BL and non-lymphoid cell lines. Genes with 
significantly lower shRNA counts in BL are highlighted in green. right: Median logarithmic fold-
change (log2FC) for 8 BL and 6 non-BL cell lines. (C) left: Analysis of genes with differential 
shRNA representation in BL and hematopoietic-lymphoid cell lines. Genes with significantly 
lower shRNA counts in BL are highlighted in green. right: Median logarithmic fold-change 
(log2FC) for 8 BL and 5 hematopoietic-lymphoid cell lines.  common essential genes; ▽ 
common non-essential genes. (D) Logarithmic shRNA fold-changes for all shRNAs targeting 
PAX5, FLI1 and ALLC in cell lines from our BL or the Cellecta RNAi screen. 
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For future validation studies we selected 2 independent shRNAs targeting genes with 
significant lower shRNA counts in BL compared to non-lymphoid cell lines and a mean 
depletion of -0.5 in BL (Figure 37).  
 
Figure 37: Selection of shRNAs targeting entity-specific essential genes 
The heatmap shows logarithmic fold-changes of shRNAs that target genes essential in BL, but 
not in non-lymphoid cell lines. For every gene, two independent shRNAs that were significantly 
lower in BL and had a mean logarithmic fold-change of -0.5 were selected.  
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4.6 Summary 
We investigated mechanisms of evading apoptosis in MYC-driven Burkitt lymphoma. Besides of 
aberrations in the TP53 gene, mutations within the conserved MYC box I were shown to 
promote survival. In our analysis of 67 BL primary samples, 43% of BL patients carried 
mutations in TP53 and 27% in MYC box I. Most importantly, both mutations were not exclusive 
and in about 50% of BL patients genetic aberrations that contribute to the evasion of MYC-
induced apoptosis were not known. 
To identify alternative mechanisms, we correlated TP53 mutation with clinical parameters and 
chromosomal aberrations. Patients carrying mutant TP53 displayed with higher clinical stage 
and advanced disease. However, overall survival was independent of TP53 status, indicating 
that additional factors contribute to the aggressiveness of the disease. In patients retaining 
wild-type p53 (p53wt) we observed a high frequency of chromosome 1q gains, mainly partial 
trisomies, leading to upregulation of cancer consensus genes within minimally gained regions.  
Essential genes specific to p53wt BL were studied in an unbiased functional genomics 
approach. We performed an RNAi screen in a panel of representative cell lines using a pooled 
shRNA library targeting genes beyond chr1q. Results obtained from the screen were robust 
and sensitive for identification of common as well as genotype-specific gene dependences. We 
identified the p53 inhibitor MDM4 as the strongest p53-dependent essential gene. Effects seen 
in the screen were highly reproducible and p53-dependence was confirmed in a p53 knock-out 
model. 
Depletion of MDM4 in p53wt cell lines activated the p53 pathway resulting into p53 target 
gene expression, downregulation of proliferation signals (E2F targets, G2M checkpoint, MYC 
targets) and cell cycle arrest. In a mouse xenograft model, knock-down of MDM4 significantly 
reduced tumor growth, suggesting MDM4 as a promising therapeutic target. Moreover, a 
specific dependence of p53wt cell lines on MDM4 could be shown in a meta-analysis of a large 
genome-wide RNAi screen across cancer entities.  
To understand the molecular impact of TP53 mutations in aggressive B-cell lymphoma we 
derived a gene expression signature discriminating between patients with and without p53 
mutation. MDM4 was exclusively upregulated in Burkitt lymphoma, but not in diffuse large B-
cell lymphoma, while p53 pathway activity was reduced.  
p53-specific effects were also validated for an additional candidate gene from our RNAi screen, 
CDKN3. Our data suggest a yet unknown mechanism of cell cycle regulation in the presence of 
wild-type p53. Furthermore, we expanded the data analysis of our RNAi screen to identify 
entity-specific vulnerabilities and distinguished Burkitt lymphoma and B-cell lymphoma 
essential genes that inquire further studies. 
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5 Discussion 
Oncogenic MYC activation is the hallmark of Burkitt lymphoma (BL), but is not sufficient for 
tumorigenesis. Essential survival and proliferation signals are provided by mutations that 
activate the E2A transcription factor, tonic B-cell receptor signaling and PI3K signaling. In 
addition, the p53 tumor suppressor pathway is inactivated in 40% of BL by mutations of the 
TP53 gene, but alternative mechanisms to escape MYC-driven p53 response in the remaining 
60% are not known. In this study, we identified an association of chr1q32 gain with wild-type 
p53 patients. We further provide a functional genomics resource for identification of gene 
dependences in cell line models with defined p53 status. Among the candidate genes 
identified in an unbiased screening approach, the p53 inhibitor MDM4 was identified as an 
essential gene in BL retaining functional wild-type p53. 
5.1 Recurrent genetic aberrations in Burkitt Lymphoma 
Burkitt lymphoma is seen as a relatively homogeneous disease. Translocation of MYC is a 
hallmark characteristic of all BL and mutations that activate E2A transcription factor are found 
in 70% of BL. In addition, TP53 mutations are found in 40% of patients, indicating the need for 
additional aberrations that abrogate MYC-induced oncogenic stress responses. To study 
alternative mechanisms besides of TP53 mutation we analyzed the pattern of recurrent 
genetic aberrations in 67 BL cases (MMML consortium). MYC box I mutations, that abrogate 
activation of pro-apoptotic Bim, were previously reported to occur exclusively to TP53 
mutation65. We observed that TP53 and MYC box I mutations occurred independent of each 
other and accounted for 54% of patients, while failsafe mechanisms in the remaining 46% of 
patients still remained elusive.  
Correlation of p53 mutation status with recurrent copy number variations (CNVs) revealed an 
overrepresentation of chr1q gain in p53wt BL patients, and this observation was specific seen 
to BL, but not DLBCL. We observed a preference for partial trisomies of the proximal chr1q21-
q23 bands and an additional minimally gained region at chr1q32. Chr1q gain is the most 
frequent CNV in BL (25%)48,49,138. Sequential karyotyping in relapsed patients revealed a higher 
incidence of chr1q gain in high-grade BL at diagnosis (39%) and upon relapse (64%)139. 
However, an association with p53 mutation status has not been reported.  
Aberrations on chr1q are the most frequent CNV across cancer and mainly comprise 
amplifications or gains, rather than losses61. Cancer entities that show high frequency of chr1q 
gain include hepatocellular carcinoma (60%)140,141, breast cancer (50-60%)142,143, ovarian 
carcinoma (21%)144, multiple myeloma (40% at diagnosis, 70% at relapse)145,146 and non-
Hodgkin´s lymphoma147. Amplified regions contain multiple well characterized oncogenes 
displaying a gene dosage effect (e.g. CKS1B, MCL-1, UCK2).  
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5.2 RNAi screen identifies p53-specific vulnerabilities  
Analysis of the genetic landscape of BL greatly improved our understanding of its 
pathogenesis. However, the molecular impact of genetic aberrations is often not fully 
understood. Copy number variations affect large chromosomal regions and the contribution of 
single genes to tumorigenesis is not known. Genetic perturbation screens are a powerful 
technology to identify genes that are essential for cell proliferation or viability in an unbiased 
approach. The Broad Institute performed an RNAi screen in a large panel of cell lines across 
cancers and observed that cell lines carrying hotspot mutations in BRAF or KRAS strongly 
depend on the activated oncogene113. Melanoma patients carrying the BRAF V600E mutation 
were treated in clinical trials with the small molecule inhibitor vemurafenib that specifically 
inhibits the mutant isoform148, but some patients acquire resistance149. RNAi screening in cell 
lines was used to identify resistance mechanisms that could guide future therapeutic 
approaches150. The oncogene KRAS is deemed to be an undruggable target for cancer therapy. 
Therefore, synthetic lethality screens were performed to find alternative druggable targets in 
KRAS mutant cancer151-153. As shown on cell lines from the Achilles project, loss-of-function 
mutations in tumor suppressors can lead to dependence on close homologs that compensate 
for the loss. Inactivating mutations in ARID1A, a member of the SWI/SNF nucleosome 
remodeling complex, are found in many human cancers and promote tumor formation. RNAi 
screen revealed that depletion of its homolog ARID1B is toxic to ARID1A mutant cancer cell 
lines154. These examples demonstrate that RNAi screens in representative cell line models are 
useful tools to assess differential functional dependences in defined subgroups beyond genetic 
characteristics. 
To identify genes essential in MYC-driven BL that do not acquire TP53 mutation we performed 
a shRNA screen in BL cell line models representing genetic patient subgroups. Four p53 wild-
type (p53wt) BL cell lines that carried a chr1q gain were compared to four p53 mutant 
(p53mut) cell lines with normal copy number. A pooled shRNA library consisting of 27,500 
shRNAs targeting more than 5,000 genes was used. For an unbiased approach we decided to 
use a shRNA library that was not limited to genes located on chromosome 1q, even though 
genetic data suggested p53-specific functions for this region. 237 of these genes were located 
on chr1q. ENSEMBL BioMart lists 945 protein coding genes on chr1q. Therefore, we covered 
25% of all genes on chr1q, including characterized oncogenes.  
As an indication of data robustness, common essential and non-essential genes across cell lines 
defined in a previous study115 showed high concordance. Common essential genes were 
among the genes with the strongest shRNA depletion and were significantly enriched for 
proteasomal, ribosomal and spliceosomal genes, while non-essential genes showed unchanged 
shRNA counts and no enriched gene sets. Importantly, these effects were independent of the 
p53 mutation status. A high dynamic range allowed us to reliably distinguish between essential 
and non-essential genes.  
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To identify differential shRNA loss in genetically defined subgroups we combined two data 
analysis pipelines that were previously applied to pooled shRNA screens. The first pipeline 
compares differences in shRNA counts in two groups irrespectively of the actual depletion of 
shRNAs113. The second pipeline is a measurement of the strength of shRNA depletion and 
therefore the toxicity effects of the gene knock-down131,132. As described above, cell lines 
carrying BRAF or KRAS mutations strongly depend on the activated oncogene and RNAi screen 
identified both genes as the highest ranking genes based on differential shRNA representation 
in mutant versus wild-type cell lines. We tested the reliability of our screen to identify 
genotype-specific viability effects. The BL-2 cell line carries a MYD88 mutation leading to 
activation of interleukin and Toll-Like receptor pathway. As shown previously in DLBCL of the 
ABC-subtype, MYD88 mutant cell lines depend on MYD88 itself and its downstream target, 
IRAK1136. By comparison of differential shRNA losses in BL-2 versus seven remaining cell lines 
we identified both MYD88 and IRAK1 among the highest-ranking genes with significant lower 
shRNA counts in the MYD88-mutant cell line. This example serves as a positive control 
demonstrating that we can identify genotype-specific effects even within single cell lines. 
By comparison of differential shRNA losses in four p53wt and four p53mut BL cell lines we 
identified 12 candidate genes that were essential specifically in p53wt cell lines. Four genes, 
including two metabolic proteins (GALNTL4, CYP39A1) and two modulators of transcription 
(BHMT2, HIST3H3), were found to be essential in both groups of cell lines, but the dependence 
was stronger in p53wt cell lines. The highest ranking gene that was essential only in the 
presence of wild-type was the p53 inhibitor MDM4 that is located on chr1q32. Besides of 
MDM4 only HIST3H3 was located on chr1q and we did not observe an enrichment of 
genotype-specific essential genes by chromosomal location. A second candidate gene chosen 
for validation was the cell cycle regulator CDKN3.  
5.3 MDM4 in Burkitt Lymphoma 
The tumor suppressor p53 is the most frequently mutated gene in human cancer. p53 senses 
cellular stress such as DNA damage, hypoxia or oncogene activation and prevents uncontrolled 
proliferation and malignant transformation by transactivation of multiple target genes that 
regulate DNA repair, cell cycle, apoptosis, senescence, differentiation, metabolism and 
angiogenesis155. Over 80% of mutations occur in the DNA binding domain and many mutations 
inactivate its transcriptional activity156,157. p53 mutations are found on average in 50% of 
human cancers. However, the incidence strongly varies by entity and ranges from 5% in renal 
cell carcinoma and 10% in melanoma to 70% of small cell lung cancer and 90% in ovarian 
cancer158,159. The high incidence of p53 mutations in cancer suggests that probably all tumor 
cells inactive this tumor suppressor pathway, either by p53 mutation or by alternative 
mechanisms. Identification of factors that suppress p53 response may constitute an important 
strategy to develop targeted therapies based on the restoration of p53 activity. 
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We identified MDM4 as an essential gene in Burkitt lymphoma cell lines without p53 mutation. 
p53-dependence was confirmed in an isogenic p53-/- cell line. MDM4 and its close homologue 
MDM2 are the two major p53 inhibitors consisting of a highly conserved C-terminal p53 
binding domain, an internal acidic domain and an N-terminal RING finger domain82,84. Binding 
to the N-terminal transactivation domain of p53 suppresses p53-mediated transcription160. 
MDM2, but not MDM4, acts as an E3-ubiquitin ligase and targets p53 for proteasomal 
degradation83. This process involves the RING finger domain of MDM2 and its less conserved 
acidic domain161. The RING finger domain also mediates homo- and heterodimerization of 
MDM2 and MDM4, an important regulatory element which can both stabilize or destabilize 
the proteins162,163. Mutations within the RING finger domain and loss of either MDM2 or 
MDM4 are embryonic lethal in the presence of p53 and concomitant loss of p53 rescues the 
observed toxicity, demonstrating that both MDM proteins are needed for full suppression of 
p53164-168. In unstressed cells, MDM4 evades MDM2-mediated degradation by association with 
the deubiquitinase HAUSP. Stabilized MDM4 translocates MDM2 to the nucleus and protects it 
from self-ubiquitination169,170. Therefore, MDM4 can indirectly influence p53 level by 
regulation of MDM2. Upon DNA damage, MDM4 is phosphorylated by ARF which decreases 
binding affinity towards HAUSP and increases association with 14-3-3 protein, which redirects 
the E3-ubiquitin-ligase activity of MDM2 from p53 towards MDM4171,172. While MDM2 is a 
transcriptional target of p53 and inhibits p53 activity in a negative feedback loop, MDM4 is 
constitutively expressed independent of p53 and regulated on a post-transcriptional and post-
translational level160. 
MDM2 and MDM4 are often overexpressed in a mutually exclusive pattern in cancers that 
retain wild-type p53173. Amplification of the MDM4 locus on chr1q32 was first described in 
glioblastoma174 and further characterized by the Cancer Genome Atlas Research Network. 
Focal gains of MDM4 were detected in 4% of gliomas and were mutually exclusive to MDM2 
amplifications on chr12q15, that occurred in 11%, or p53 aberrations present in 38% of 
untreated and 58% of treated patients175. MDM4 is also amplified in 10-14% of breast cancer, 
while MDM2 amplification is seen in about 4%159,176,177. MDM4 and TP53 aberrations were 
mutually exclusive (p=0.013) and MDM2 showed tendencies towards exclusivity with MDM4 
amplification and TP53 aberrations159. In a mouse xenograft model, MDM4 amplification 
promoted clonal outgrowth178. In 17% of soft tissue sarcomas MDM4 was found to be 
amplified179. A more detailed analysis revealed a subtype-specific pattern for MDM4 and 
MDM2 amplifications. Both genes were equally amplified in osteosarcoma (MDM2/MDM4, 
35%/35%), while MDM2 prevailed in well-differentiated liposarcoma (70%/0%) and de-
differentiated liposarcoma (50%/13%) and MDM4 was more frequently amplified in Ewing´s 
sarcoma (38%/50%) and synovial sarcoma (33%/44%)180. Prevalence for MDM4 amplification 
was also observed in retinoblastoma (10%/65%) and ectopically overexpressed MDM4 in Rb-
deficient retinal cells promoted retinoblastoma181. Notably, elevated MDM4 protein level was 
detected in 65% of cutaneous melanoma, a disease that rarely acquires TP53 mutations (17%) 
and poorly responds to chemotherapy. MDM4 overexpression was not observed on mRNA 
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level and MDM4 amplifications are rare (8%)159. These findings suggest that the role of MDM4 
deregulation in cancer might be underestimated. In BL, little is known about the role of MDM4. 
One study in pediatric BL identified MDM4 amplification in 5/25 patients which was correlated 
with elevated mRNA level, but not with protein level182. Amplifications of chr1q are the most 
frequent copy number alteration in BL49. In our study, we show for the first time an association 
of chr1q32 gain with wild-type p53 in BL patients.  
MDM2 and MDM4 amplifications often occur exclusive to each other and overexpression of 
one member is sufficient to suppress p53. The distinct pattern of amplifications indicates yet 
unknown specific molecular mechanisms for MDM2 and MDM4. Overexpression of MDM4 
overcomes cellular senescence triggered by oncogenic Ras activation in murine and human 
fibroblasts176,183,184. In addition, pro-survival signaling through the PI3K/AKT/mTOR signaling 
axis in hepatocellular carcinoma was shown to suppress the p53 pathway by phosphorylation 
and stabilization of MDM4185.  
Restoration of p53 activity by targeting of MDM2 and MDM4 is a promising therapeutic 
approach. The small molecule inhibitor nutlin-3 was identified in a chemical screen for 
compounds that target the p53-binding pocket of MDM2 and therefore competes with p53 
binding186. Nutlin-3 activates the p53 pathway in cancer cell lines without TP53 mutation187 
and induces cell cycle arrest or apoptosis in a cell line dependent context188. Factors that 
influence the decision on p53 response were studied in a synthetic lethality screen, but are still 
incompletely understood189. Thereby, the use of nutlin-3 as a single agent in the clinic is 
limited190,191. In combination with genotoxic reagents or cyclin-dependent kinase inhibitors, 
nutlin-3 synergizes in the induction of apoptosis187,192,193. The strong conservation and high 
structural similarity of the p53 binding pocket with MDM4 suggested dual-specificity194. 
However, nutlin-3 shows much lower binding affinities for MDM4 and MDM4 overexpression 
can confer resistance towards nutin-3 induced apoptosis195,196. A small-molecule inhibitor with 
high specificity for the MDM4 p53-binding site197 showed anti-proliferative effects in p53 wild-
type HCC cell lines185. However, the efficiency of this inhibitor was limited by the instability of 
the MDM4-inhibitor complex198. The development of peptide inhibitors did not result into 
promising therapeutic reagents so far, mostly hampered by poor biochemical properties199. 
Modification of α-helical peptides modified with side chains, such as hydrocarbons, result into 
so called stapled peptides with increased cell permeability and stability200. The stapled peptide 
SAH-p53-8 that mimics the p53 α-helical peptide shows high binding affinity towards MDM4 
and exerts cytotoxic effects in HCC cell lines by activation of the p53 pathway201. The peptide 
was also shown to be active in cutaneous melanoma202 and uveal melanoma203.  
Following MDM4 knock-down, we observed activation of the p53 pathway and cell cycle arrest 
in BL cell lines. For future therapeutic approaches, understanding the switch between cell cycle 
arrest and apoptotic response is of great importance. The sensitivity of p53wt BL cell lines 
towards MDM2 knock-down and nutlin-3 suggests that dual inhibition might be more 
effective. Reasonable drug combinations of p53 reactivation and DNA-damaging reagents may 
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show improved cytotoxic effects. MDM4 was also identified as a gene significantly more toxic 
in p53wt cancer cell lines across entities, emphasizing that MDM4 is a promising therapeutic 
target. 
5.4 Potential role of the cell cycle regulator CDKN3 in the p53 pathway  
We identified CDKN3 as a specifically essential gene in Burkitt lymphoma with wild-type p53. 
CDKN3 is a dual-specificity phosphatase that removes phosphorylation from serine as well as 
threonine and controls chromosomal integrity during mitosis in three major ways: (1) CDKN3 
inactivates CDK2, a key initiator of G1-S transition, and hereby induces G1 checkpoint arrest204-
206. (2) CDKN3 dephosphorylates CDK1 during mitotic exit. Knock-down of CDKN3 increases the 
number of centrosomes and weakens spindle assembly checkpoint which can subsequently 
lead to aneuploidy207. (3) CDKN3 directly targets Mps-1 (monopolar spindle 1), a regulator of 
centrosome duplication, formation and chromosomal spindle attachment that is activated 
during mitosis by CDK2208. Depletion of CDKN3 leads to excess Mps-1 levels resulting into 
overduplication of centrosomes and multinucleated cells209. 
In our study CDKN3 knock-down in BL cell lines decreased proliferation and induced G1 cell 
cycle arrest. This is in line with previous studies in cervical cancer lines204,210,211 and the 
hepatocellular carcinoma cell line Huh-7212. In HeLa cells, a strong increase of CDKN3 
expression was observed during G1-S transition, which could explain the preference for G1-
arrest204.  
CDKN3 was found to be overexpressed in many cancers, including renal cell carcinoma213, 
hepatocellular carcinoma214, thyroid cancers215, cervical cancer211, ovarian carcinoma216, breast 
and prostate cancer210. Overexpression was not caused by amplification of the CDKN3 
chromosomal location on chr14q22 and the mechanism of CDKN3 regulation is still unknown. 
It might be a surrogate marker for proliferating cells. However, it was not tested if CDKN3 level 
fluctuated during cell cycle as shown for HeLa cells204. High CDKN3 level was frequently 
observed to be associated with higher tumor grade and poor patient outcome213,214,216,217. 
During B cell differentiation CDKN3 expression was characteristic for germinal center B cells of 
the dark zone, while a strong downregulation in light zone B cells was observed9. Therefore, 
high CDKN3 expression might be an additional centroblast-specific characteristic that is 
retained during transformation of post-germinal center B cells. Burkitt lymphoma is 
characterized by a high proliferation rate (Ki67>95%), but CDKN3 expression level were not 
reported yet. Analysis of published microarray data showed that CDKN3 was highly expressed 
in studies on aggressive B-NHL, and especially studies including Burkitt lymphoma (Figure 38A). 
In the study of Hummel et al. (2005), that was used to derive a molecular signature for Burkitt 
lymphoma, CDKN3 was significantly overexpressed in the group of molecular Burkitt 
lymphoma, compared to non-Burkitt lymphoma (DLBCL) (Figure 38B). 
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Figure 38: Microarray data on CDKN3 expression in aggressive lymphomas 
(A) Expression of CDKN3 in publically available gene expression studies using Affymetrix U133a 
microarray. The visualization was created by the R2 platform (http://r2.amc.nl). Highlighted 
are studies including aggressive B-NHL (MMML consortium). (B) CDKN3 expression level in 215 
aggressive B-NHL by molecular classification. (green: molecular Burkitt lymphoma – mbl; blue: 
non-molecular Burkitt lymphoma – non-mbl; red: intermediated cases) 
 
CDKN3 expression did not contribute to the p53 signature that differentiated p53wt and 
p53mut cases. However, we observed p53-specific effects in our cell line models. MDM4 
knock-down led to p53-dependent depletion of CDKN3 mRNA. In a time course experiment, 
CDKN3 depletion seems to occur with a delay following activation of the p53 pathway. The 
exact mechanisms by which CDKN3 might be regulated, is unknown. A previous study showed 
that the p53 target p21, that mediates cell cycle arrest, was inversely correlated with CDKN3, 
and p21 knock-down increased CDKN3 levels218. The phosphatase Cdc25a exerts similar 
functions than CDKN3 and is a well characterized oncogene219. Cdc25a is a transcriptional 
target of MYC and mediates G1-S transition by activation of the CDK2/cyclin E complex220. 
Moreover, Cdc25a competes with p21 for CDK2-binding and is therefore counterbalancing the 
tumor suppressive function of p53221. Upon DNA damage, Cdc25a is downregulated by a 
mechanisms involving checkpoint kinase 1 (Chk1)222. p53 can lead to downregulation of Cdc25a 
by transcriptional activation of miR-365 that targets Cdc25a mRNA for degradation223.  
Upon CDKN3 depletion we observed upregulation of p53 target genes. Whether these effects 
are direct or indirect via DNA stress response is currently unclear.  
5.5 BL-specific vulnerability  
Our study was designed to identify p53-specific essential genes. To further understand the 
pathogenesis of BL we wanted to also identify entity-specific essential genes. The Achilles 
Hummel  
(n=215) 
Siebert 
(n=36) 
Kreuz  
(n=148) 
A B 
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project included 216 cell lines, but Burkitt lymphoma was not represented112. One study on the 
pathogenesis of BL included a RNAi drop-out screen in several BL cell lines, but the shRNA 
library was restricted to selected genes mainly within the B-cell receptor pathway44. Therefore, 
our screen is the largest and most comprehensive genetic perturbation screen in Burkitt 
lymphoma. To find entity-specific essential genes, we combined our data set with three RNAi 
screens performed by Cellecta.  
We identified the genes PAX5 and FLI1 as the most robust candidate genes. In a comparison of 
BL versus other haematopoietic/lymphoid cell lines we also identified PAX5 as one of the 
highest scoring genes. In a recent genetic perturbation screen using genome-wide CRISPR/Cas9 
sgRNA libraries, PAX5 was identified as one of the top candidate genes that was essential in 
two BL cell lines, but dispensable in two CML cell lines126. PAX5 is a transcription factor of the 
conserved paired box (PAX) protein family. It is highly expressed in all mature B-cells except for 
plasma cells and initiates B-cell specific programs both by activation and repression of its 
target genes224,225. PAX5 deregulation has been implicated in the pathogenesis of B cell 
malignancies, such as acute lymphoblastic leukemia and some non-Hodgkin´s lymphomas. 
Deletion of PAX5 on 9p13 has been described in some cases, as well as translocation to various 
sites within the genome, that can either activate or deactivate PAX5. Therefore, PAX5 can 
function as a tumor suppressor or oncogene226-228. Chromosomal aberration of PAX5 has not 
been described in BL and further studies are needed to clarify, why PAX5 is essential in all BL 
cell lines, but not in other B-cell derived lymphoma cell lines.  
The transcription factor FLI1 (Friend Leukemia integration factor, synonym ERGB) was 
identified in our RNAi screen comparison as an essential gene in BL as well as non-BL cell lines 
of the lymphoid lineage. We compared published RNA sequencing data in more than 600 cell 
lines and found an overexpression of FLI1 in lymphoid compared to non-lymphoid cell lines133. 
FLI1 belongs to the ETS (E26 transformation specific) transcription protein family and plays a 
key role in normal hematopoiesis by regulation of stem cell maintenance and differentiation229-
231. This proto-oncogene was first identified in erythroleukemias induced by Friend Murine 
Leukemia Virus-infected erythroblasts232. However, overexpression of FLI1 in transgenic mice 
induces B cell lymphomas rather than erythroleukemias233. Besides of virally induced tumors, 
FLI1 has been shown to be involved in the pathogenesis of the pediatric bone cancer Ewing´s 
sarcoma that is positive for the EWS-FLI1 fusion protein in 80% of the cases234. High level of 
FLI1 can also provoke autoimmune diseases, such as systemic lupus erythematosus. The 
multiple involvements of FLI1 in disease formation motivated attempts to develop FLI1-specific 
inhibitors235. Topoisomerase inhibitors were also reported to work in part by FLI1 inhibition in 
Ewing´s sarcoma236,237. FLI1 is not described to be deregulated in BL and its role in 
leukemogenesis has to be evaluated in further studies.  
The identification B cell specific vulnerabilities using RNAi screens enables development of 
targeted therapies with reduced overall toxicity compared to chemotherapeutic reagents.  
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6 Conclusion and Perspective 
Insights into the pathogenesis of Burkitt lymphoma beyond oncogenic MYC activation were 
gained from molecular and genetic profiling. Here we describe the association of chr1q gain 
with wild-type p53. Using an RNAi screen in a panel of representative cell lines we were able to 
identify essential genes and to link specific gene dependences to the genotype. We identified a 
strong dependence of the BL-2 cell line on the mutated MYD88 oncogene, as well as 
downstream members of the associated signaling pathway, proving the validity of our 
approach. Moreover, we identified p53-specific gene dependences in BL. Integration of 
observed genetic dependences and molecular patient profiles revealed, that amplification and 
overexpression of MDM4 contributes to BL pathogenesis in the absence of p53 mutations. We 
identified MDM4 as the main target of chr1q amplification essential for cell propagation. 
MDM4 also ranked among the prime candidate genes when our analysis was expanded to a 
large genome-wide RNAi screen across cancer. Therefore, reactivation of p53 following MDM4 
depletion or inhibition is a promising therapeutic approach.  
We observed p53-specific effects following knock-down of the phosphatase CDKN3 that is 
often overexpressed in cancer. So far, CDKN3 was not linked to the p53 pathway and further 
studies are needed to clarify the interaction between CDKN3 and p53. Cell cycle deregulation 
by mutation of CCND3, a cyclin that is expressed during G1/S-transition, is frequently observed 
in BL. Our data provides further evidence for the role of cell cycle regulation and safety 
checkpoints in BL and might help to find future therapeutic targets.  
BL was not represented in the Achilles project, that characterized gene dependences in 216 
cancer cell lines112, and previous genetic perturbation studies in BL were either based on 
pathway specific RNAi libraries44 or limited in the number of cell lines126. Our data set presents 
the most comprehensive study on genetic vulnerabilities in BL. Beyond the scope of our p53-
based project, we identified entity-specific genes by integration of multiple RNAi screens. 
Validation and functional characterization is still ongoing, but based on our previous 
experience, data obtained from the drop-out screen is very robust and reproducible. We 
conclude that functional screens are a valuable resource for identification of cellular context-
specific essential genes. The novel CRISPR-technology rapidly evolves as an alternative to RNAi 
and may guide future genetic perturbation screens. Combination with primary patient data 
adds an additional layer to omics data and greatly improves our understanding of pathogenic 
mechanisms in cancer.  
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